

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Vitamin D status and risk of chronic low back pain: a nested case-control analysis in the HUNT Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018521
Article Type:	Research
Date Submitted by the Author:	07-Jul-2017
Complete List of Authors:	Heuch, Ingrid; Oslo University Hospital, Department of Research, Innovation and Education, Division of Clinical Neuroscience Heuch, Ivar; University of Bergen, Department of Mathematics Hagen, Knut; Norwegian University of Science and Technology, Department of Neuroscience; St. Olavs Hospital, Norwegian National Headache Centre, Department of Neurology Mai, Xiao-Mei; Norwegian University of Science and Technology, Department of Public Health and Nursing, Faculty of Medicine and Health Science Langhammer, Arnulf; Norwegian University of Science and Technology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences Zwart, John-Anker; Oslo University Hospital, Department of Research, Innovation and Education, Division of Clinical Neuroscience; University of Oslo, Faculty of Medicine
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Public health
Keywords:	EPIDEMIOLOGY, Vitamin D AND low back, Back pain < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts

Vitamin D status and risk of chronic low back pain: a nested case-control analysis in the HUNT Study

Ingrid Heuch,¹ Ivar Heuch,² Knut Hagen,^{3,4} Xiao-Mei Mai,⁵ Arnulf Langhammer,⁵ John-Anker Zwart^{1,6}

¹Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway

²Department of Mathematics, University of Bergen, Bergen, Norway

³Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway

⁴Norwegian National Headache Centre, Department of Neurology, St. Olavs Hospital, Trondheim, Norway

⁵Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

⁶Faculty of Medicine, University of Oslo, Oslo, Norway

Correspondence to

Ingrid Heuch, MD, PhD, Department of Research, Innovation and Education, Oslo University Hospital, P.O. Box 4956 Nydalen, N-0407 Oslo, Norway.

E-mail: ingrid.heuch@ous-hf.no

Telephone +4790684232

Word count: 2872

ABSTRACT

Objective: To explore potential associations between vitamin D status and risk of chronic low back pain (LBP) in a Norwegian cohort, and to investigate whether relationships depend on the season of blood sample collection.

Design: A nested case-control study in a prospective data set.

Setting: The Norwegian community-based Nord-Trøndelag Health Study (HUNT). Data were collected in the HUNT2 (1995-1997) and HUNT3 (2006-2008) surveys.

Main outcome measure: Chronic LBP, defined as LBP persisting at least 3 months continuously during the past year.

Participants: Among individuals aged 19-55 years without LBP in HUNT2, a data set was generated including 1685 cases with LBP in HUNT3 and 3137 controls without LBP.

Methods: Blood samples from the participants collected in HUNT2 were analysed for serum 25-hydroxyvitamin D (25(OH)D) level. Associations with LBP were evaluated by unconditional logistic regression analysis with adjustment for age, sex, work status, physical activity at work and in leisure time, education, smoking and BMI.

Results: No association between vitamin D status and risk of chronic LBP was found in the total data set (OR per 10 nmol/l 25(OH)D =1.01, 95% CI 0.97 to 1.06) or in individuals with blood samples collected in summer/autumn (OR per 10 nmol/l 25(OH)D =0.99, 95% CI 0.93 to 1.06). For blood samples drawn in winter/spring associations differed significantly between women and men ($p=0.004$). Among women a positive association was seen (OR per 10 nmol/l 25(OH)D =1.11, 95% CI 1.02 to 1.20), but among men no significant association was observed (OR per 10 nmol/l 25(OH)D =0.90, 95% CI 0.81 to 1.01).

Conclusions: Overall, no association between vitamin D status and risk of LBP was demonstrated. The association suggested in women for the winter/spring season cannot be regarded as established.

KEYWORDS

back pain, musculoskeletal, vitamin D, epidemiology

Strengths and limitations of this study

-The study provides information about the potential association between vitamin D status and risk of chronic low back pain (LBP).

-The study is population-based and prospective.

-Season of blood sample collection for analysis of serum 25(OH)D is taken into account in the analysis.

-Vitamin D and LBP status were not registered in the intermediate period between baseline and end of follow-up.

For peer review only

INTRODUCTION

Low back pain (LBP) is one of the most common musculoskeletal disorders and often leads to sick leave and a high degree of disability with substantial costs for society.[1] The causes of non-specific LBP are not sufficiently understood.[2]

Vitamin D is required for absorption of calcium from the intestines, and vitamin D has shown positive health effects on the muscle and skeletal system.[3] Skeletal muscles have vitamin D receptors and may require vitamin D for maximum function.[4] Associations between vitamin D deficiency and incidence of chronic pain have been suggested in various studies, but the evidence is not conclusive.[5] Some studies have found associations between vitamin D deficiency and occurrence of non-specific musculoskeletal pain in patient materials[6] and in population-based data sets.[7]

Very few population-based studies have been carried out regarding associations between vitamin D status and occurrence of back pain,[8] in particular with a prospective design. Studies of associations between vitamin D status and back pain have mostly been based on relatively small data sets involving patients, with some studies[9, 10, 11, 12, 13] suggesting an association between low vitamin D levels and back pain, while other studies[14, 15, 16] were unable to demonstrate any relationships. A cross-sectional study among schoolchildren also indicated such an association.[17]

Potential associations between vitamin D deficiency and LBP have partly been ascribed to osteomalacia[11], with an accumulation of osteoid because of defective mineralization. Poor muscle strength induced by vitamin D deficiency[3] may also affect the experience of LBP. It is not certain, however, whether these factors play any role considering the incidence of low back pain at the population level.

Only prospective studies can show whether vitamin D levels affect the subsequent risk of experiencing LBP. It is possible that back pain conversely can affect vitamin D status,[10] perhaps through modified behaviour influencing exposure to sunlight or through nutritional factors, and for this reason it is essential to base conclusions on results from prospective studies. It is important to carry out adjustment for potential confounders such as obesity, which is related to both vitamin D levels and to risk of low back pain.[18, 19, 20] Vitamin D

1
2
3 levels are higher after sun exposure, with the prevalence of vitamin D deficiency varying
4 seasonally,[21] so associations should also be assessed separately for the summer/autumn and
5 winter/spring seasons.
6
7

8
9
10 This study will investigate whether an association can be established between vitamin D
11 status and risk of LBP in a case-control study nested in a Norwegian cohort. Vitamin D status
12 is based on measurement of the major circulating metabolite 25-hydroxyvitamin D
13 (25(OH)D).[22] The importance of seasonality for blood sample collection for vitamin D
14 measurement will be explored.
15
16
17
18
19
20
21

22 **METHODS**

23 **Participants**

24
25
26 The present work is based on information from the Nord-Trøndelag Health Study (HUNT).
27 From 1995 to 1997, the large health survey HUNT2 was conducted in Nord-Trøndelag county
28 in Norway. The entire adult population received a health questionnaire and participants
29 underwent a clinical examination, including measurements of body weight and height.[23]
30
31 One question dealt with chronic LBP defined as LBP lasting at least three months
32 continuously within the past year. Blood samples were drawn at the clinical examination. In
33 the HUNT3 survey, conducted in 2006 to 2008 in the same county with a corresponding
34 target population, similar questionnaires were distributed.[23] Information about residence
35 status was supplied by national registries and linked by use of the unique Norwegian personal
36 identification numbers.
37
38
39
40
41
42
43
44

45 A nested case-control study was conducted using prospective data from HUNT2 regarded as
46 baseline and HUNT3 regarded as follow-up, including 4822 individuals in the age range 19-
47 55 years when attending HUNT2. Vitamin D status was assessed on the basis of blood
48 samples from the participants collected in HUNT2. Participants belonged to three different
49 subsamples. The first and second subsample consisted of random samples from HUNT2 and
50 were established in connection with previous studies of the association between vitamin D
51 and asthma and lung function,[24, 25] but in the current study all individuals with LBP in
52 HUNT2 were excluded. The first subsample was analysed for 25(OH)D in 2010, and included
53 altogether 1492 persons, comprising 247 cases (individuals with LBP in HUNT3) and 1245
54
55
56
57
58
59
60

controls (individuals without LBP in HUNT3). The second subsample with analysis date for 25(OH)D in 2015 included a total of 2051 persons, comprising 343 cases and 1708 controls. The third subsample had measurements of 25(OH)D carried out in 2014/2015 and consisted of 1279 persons without LBP in HUNT2. Of these, a total of 1095 cases were selected at random among persons suffering from LBP in HUNT3 and 184 controls were randomly selected among persons without LBP in HUNT3. The third subsample was solely established for the current nested case-control study. None of the individuals included in this study had missing values for any covariate considered.

The original plan was that the case-control study would consist of the combined first and third subsamples only, and the size of the third subsample was adapted to power requirements in this data set. The second subsample only became available at a later stage.

Exposure

Blood samples collected in HUNT2 were stored at -70 °C until analysis. The level of 25(OH)D in serum was measured in the years 2010 and in 2014/2015 by chemiluminescent immunoassay (CLIA) methodology, using Liaison 25-OH Vitamin D Total assay (DiaSorin Inc., USA). Another kit from DiaSorin was used from 2014, but a conversion factor was used to obtain comparable values.

Serum 25(OH)D levels were classified into three groups <50.0 nmol/l, 50.0-74.9 nmol/l and ≥75.0 nmol/l, which are widely used categories in studies of vitamin D levels. Values <50.0 nmol/l are usually regarded as representing vitamin D deficiency.[26]

Covariate assessment

Baseline age was categorized into 10-year intervals. Four categories of work status were defined, the first comprising people being employed or carrying out professional work. The second category included those temporarily out of work, students and individuals in military service. The third category included pensioners and people receiving social security support, and the fourth category represented women occupied full-time with housework. Those currently working supplied information about physical activity at work,[27] in four categories

1
2
3 representing substantially sedentary work, work involving extensive walking, work leading to
4 both walking and lifting, and work involving particularly strenuous activities. For physical
5 activity in leisure time, including going to work, one category included those engaged in light
6 activity only or hard physical activity (leading to sweating or being out of breath) <1 hour per
7 week.[28] Other categories represented hard physical activity 1-2 and ≥ 3 hours per week.
8
9

10
11 Education was grouped according to duration as ≤ 9 , 10-12, or ≥ 13 years. Categories of
12 cigarette smoking represented current daily smoking, previous daily smoking and never daily
13 smoking. BMI, defined as weight/height² and computed in kg/m², was subdivided into three
14 groups: <25, 25-29.9, ≥ 30 .
15
16
17

18
19 Season of blood sample collection was categorized as either the summer/autumn season (June
20 through November) or the winter/spring season (December through May). This subdivision
21 gives a marked difference in vitamin D deficiency between 6-months periods.[21]
22
23
24
25
26
27

28 **Statistical methods**

29
30 Associations between 25(OH)D levels in serum and risk of chronic LBP were assessed by
31 unconditional logistic regression analysis with adjustment for potential confounders. Analyses
32 were performed separately with 25(OH)D levels as categorical and continuous variables. All
33 other variables were considered categorical. First, adjustments were carried out for age and
34 sex and a factor indicating which subsample each individual belonged to. Additional
35 adjustments for work status, physical activity at work and in leisure time, education, smoking,
36 BMI and season of blood sample collection were then introduced. Separate tests were
37 performed for interaction between continuous 25(OH)D level and all variables adjusted for.
38 Linearity in the association with continuous 25(OH)D level was tested for by adding a
39 quadratic term to the statistical model. All statistical analyses were carried out using IBM
40 SPSS version 23 (IBM Corp., Armonk, New York).
41
42
43
44
45
46
47

48
49 Separate analyses were limited to participants who had the blood samples drawn in the
50 summer/autumn season and the winter/spring season.
51
52
53
54
55
56
57
58
59
60

RESULTS

The age distribution was quite similar among cases and controls (table 1). The percentage of women was higher among cases than among controls. Within the three separate groups of serum 25(OH)D levels categorized as <50.0 nmol/l, 50.0-74.9 nmol/l and \geq 75.0 nmol/l, the percentage of persons with and without LBP at end of follow-up were almost the same among cases and controls (table 1).

Table 1 Number of individuals by age, sex, vitamin D status and case-control status

	Cases, with LBP at end of follow-up		Controls, without LBP at end of follow-up	
	Number	Percent	Number	Percent
Age groups (years)				
19-29	246	15	504	16
30-39	492	29	951	30
40-49	687	41	1191	38
50-55	260	15	491	16
Sex				
Female	1043	62	1677	54
Male	642	38	1460	47
25(OH)D (nmol/l)				
<50.0	925	55	1689	54
50.0-74.9	619	37	1126	36
\geq 75.0	141	8	322	10

LBP, low back pain.

In the total data set, the mean serum 25(OH)D levels were quite similar among cases and controls (table 2). Both in women and men the serum 25(OH)D levels were higher in the summer/autumn than in the winter/spring season among cases and controls.

Table 2 Descriptive statistics of 25(OH)D level by case-control status

	Cases, with LBP at end of follow-up				Controls, without LBP at end of follow-up			
	Number	Mean (nmol/l)	SD (nmol/l)	Median (nmol/l)	Number	Mean (nmol/l)	SD (nmol/l)	Median (nmol/l)
Total data set								
All seasons	1685	49.4	18.2	47.9	3137	50.0	19.1	48.0
Summer/autumn	773	54.1	18.4	52.0	1424	56.7	19.0	55.2
Winter/spring	912	45.4	17.0	43.8	1713	44.4	17.4	41.9
Women								
All seasons	1043	50.2	18.6	48.9	1677	50.5	19.0	49.0
Summer/autumn	480	53.8	18.7	52.9	784	56.2	18.7	54.4
Winter/spring	563	47.1	17.9	45.9	893	45.4	17.9	43.0
Men								
All seasons	642	48.0	17.4	45.8	1460	49.4	19.3	46.6
Summer/autumn	293	54.5	18.0	51.3	640	57.4	19.4	56.1
Winter/spring	349	42.6	14.9	40.8	820	43.2	16.7	40.4

LBP, low back pain; SD, standard deviation.

In the overall data set no association was found between vitamin D status and risk of LBP, neither with adjustment for age, sex and subsample nor with complete adjustment (OR per 10 nmol/l 25(OH)D= 1.01, 95% CI 0.97 to 1.06) (table 3). No significant interaction was found, but the interaction with sex was marginally significant (p=0.06). A weak positive association was suggested among women, although the estimated relation among men was in the opposite direction (table 3). Results did not differ significantly between subsamples.

Table 3 Associations between vitamin D status and risk of chronic LBP

	With adjustment for age, sex and subsample		With complete adjustment*	
	OR (95% CI)	p	OR (95% CI)	p
Total data set				
25(OH)D (nmol/l)		0.64 [†]		0.97 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	0.94 (0.80 to 1.11)		1.01 (0.85 to 1.20)	
≥75.0	0.90 (0.68 to 1.18)		0.98 (0.73 to 1.31)	
Per 10 nmol/l	0.99 (0.95 to 1.03)	0.59	1.01 (0.97 to 1.06)	0.59
Women				
25(OH)D (nmol/l)		0.54 [†]		0.27 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	1.09 (0.88 to 1.36)		1.20 (0.96 to 1.51)	
≥75.0	0.91 (0.64 to 1.30)		1.05 (0.72 to 1.52)	
Per 10 nmol/l	1.02 (0.97 to 1.08)	0.48	1.06 (1.00 to 1.12)	0.054
Men				
25(OH)D (nmol/l)		0.10 [†]		0.16 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	0.75 (0.57 to 0.98)		0.76 (0.57 to 1.01)	
≥75.0	0.90 (0.58 to 1.39)		0.88 (0.55 to 1.41)	
Per 10 nmol/l	0.94 (0.88 to 1.01)	0.10	0.94 (0.88 to 1.02)	0.13

*Adjustment for age, sex, work status, physical activity at work and in leisure time, education, smoking, BMI, subsample and season of blood sample collection.

[†]For categorical effect.

LBP, low back pain; OR, odds ratio; CI, confidence interval; BMI, body mass index.

Separate analyses of the association between vitamin D status and risk of LBP by season of blood sample collection revealed no effect in either sex in the summer/autumn season (table 4). However, in the winter/spring season associations differed significantly between women and men (p=0.004). In women a significant positive association was observed (OR per 10

nmol/l 25(OH)D =1.11, 95% CI 1.02 to 1.20) (table 4). In men the estimated association was negative (OR per 10 nmol/l 25(OH)D =0.90, 95% CI 0.81 to 1.01) but did not reach statistical significance. Considering the different OR values from the categorical analyses, a consistent trend was suggested in each sex.

Table 4 Associations between vitamin D status and risk of chronic LBP by season of blood sample collection*

	Summer/autumn		Winter/spring	
	OR (95% CI)	p	OR (95% CI)	p
Total data set				
25(OH)D (nmol/l)		0.87 [†]		0.79 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	0.93 (0.72 to 1.20)		1.08 (0.85 to 1.38)	
≥75.0	0.96 (0.66 to 1.39)		0.96 (0.58 to 1.58)	
Per 10 nmol/l	0.99 (0.93 to 1.06)	0.78	1.03 (0.97 to 1.10)	0.37
Women				
25(OH)D (nmol/l)		0.56 [†]		0.27 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	1.13 (0.81 to 1.57)		1.26 (0.92 to 1.73)	
≥75.0	0.89 (0.53 to 1.47)		1.34 (0.76 to 2.35)	
Per 10 nmol/l	1.00 (0.92 to 1.09)	0.94	1.11 (1.02 to 1.20)	0.012
Men				
25(OH)D (nmol/l)		0.15 [†]		0.20 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	0.70 (0.46 to 1.05)		0.84 (0.56 to 1.27)	
≥75.0	1.01 (0.58 to 1.76)		0.37 (0.12 to 1.17)	
Per 10 nmol/l	0.97 (0.88 to 1.08)	0.58	0.90 (0.81 to 1.01)	0.08

*Adjustment for age, sex, work status, physical activity at work and in leisure time, education, smoking, BMI and subsample.

[†]For categorical effect.

LBP, low back pain; OR, odds ratio; CI, confidence interval; BMI, body mass index.

1
2
3 No significant deviations from linearity were observed in the relationships with 25(OH)D
4 considered as a continuous variable.
5
6
7
8

9 **DISCUSSION**

10
11 The association between vitamin D status and chronic LBP was examined in a case-control
12 study nested in a population-based follow-up of a Norwegian cohort. No association between
13 vitamin D status and risk of LBP was found overall. For measurements in the winter/spring
14 season, associations differed significantly between women and men. Among women a
15 positive association was seen, but among men no significant association was observed.
16
17
18
19

20
21 A strength of the study is that the overwhelming majority of participants belonged to a
22 homogeneous ethnic group.[29] Information was available on potential confounders, which
23 made it possible to carry out accurate adjustments. The risk factor considered is represented
24 by the vitamin D status measured in blood samples drawn at the clinical examination in
25 HUNT2. However, the blood samples were stored for many years at low temperature, and the
26 measurements of serum 25(OH)D levels were carried out in 2010 or in 2014/2015. A
27 limitation is the lack of information about back pain occurring at other times in the 11-year
28 follow-up interval between HUNT2 and HUNT3. Furthermore, the extent of back pain was
29 not characterized by the participants. Another potential problem is the relatively long period
30 between collection of information about risk factors and the recording of LBP status.
31 However, vitamin D levels have been shown to be relatively stable over long periods in the
32 Norwegian population.[30]
33
34
35
36
37
38
39
40
41

42 There are few population-based studies of relationships between vitamin D status and LBP.[8]
43 Some studies have investigated such relationships among patients,[10, 12, 15] but population-
44 based studies of risk of LBP with a prospective design have been lacking. The present study is
45 to our knowledge the only prospective study of the association between vitamin D status and
46 risk of LBP.
47
48
49
50

51 In cross-sectional population-based studies, an association between low level of 25(OH)D and
52 prevalence of back pain has been found in older women[8] and in schoolchildren.[17] Some
53 case-control studies have shown an association between low levels of vitamin D and
54 occurrence of back pain,[11, 13] but others do not support an association.[14, 16] In a recent
55 small Swedish case-control study no difference in vitamin D levels could be established
56
57
58
59
60

1
2
3 between participants with chronic LBP and matched controls.[16] This is consistent with the
4 overall results found in our study.
5

6
7 Among women with blood samples drawn in the winter/spring season, we found that high
8 levels of vitamin D were associated with an increased risk of LBP, which is the opposite of
9 what was initially hypothesized. In a Danish cross-sectional study of LBP patients an
10 association in the same direction was found, and normal levels of vitamin D, as opposed to
11 vitamin D deficiency, were associated with more Modic changes in the lumbar vertebral end
12 plates as seen on MRI.[15]
13
14

15
16
17 An association between vitamin D deficiency and adiposity has been found in several
18 studies.[19] This was also confirmed in a cross-sectional study in the HUNT population.[21]
19 In a prospective study using data from HUNT2 and HUNT3, overweight and obesity were
20 found to be associated with a predisposition to chronic LBP.[20] This suggests that BMI
21 could be a confounder in the association with 25(OH)D. However, our complete analyses
22 included adjustment for BMI, and it is not to be expected that any substantial relationship
23 should remain because of the association with adiposity.
24
25
26
27
28
29

30
31 In view of the seasonal variation in sun exposure, it is important to look at the time when
32 blood samples are collected to define vitamin D deficiency.[31] Thus in a study of bone
33 mineral density the summer season was found to be the best period to determine the serum
34 25(OH)D level.[32] This contrasts with our results, with a positive association between LBP
35 and vitamin D status observed in the winter/spring season for women only. Elevated levels of
36 25(OH)D may be harmful in other respects.[33] In a study of mortality among hospitalized
37 patients a U-shaped relationship was found, with both low and high values of 25(OH)D
38 associated with increased mortality.[33, 34] However, the 25(OH)D levels had to be
39 considerably above the typical values in the present study to be associated with higher
40 mortality, so such effects at the upper end of the range for 25(OH)D are hardly relevant here.
41
42
43
44
45
46
47

48
49 Gender and sex hormone levels are important variables that can influence a possible effect of
50 vitamin D in rheumatic diseases.[35] In a Danish population receiving UVB treatment, the
51 decline in 25(OH)D varied over time between sexes, with women maintaining a greater half-
52 life of 25(OH)D.[36] It is not evident, however, how such differences can explain the sex
53 contrast seen in the present study in the association with risk of LBP.
54
55
56
57
58
59
60

1
2
3 Measurements of 25(OH)D levels made during the winter/spring season may possibly capture
4 variability of vitamin D in a better way, because vitamin D values in winter are not so
5 dependent on sunlight exposure. It is possible, however, that women tending to report LBP in
6 this population are particularly health-conscious and use more vitamin D supplements during
7 the winter/spring season, creating a false positive association. Moreover, the significant
8 relationship observed may be spurious due to the multiple statistical tests carried out. Thus
9 this association cannot yet be regarded as causal.
10
11
12
13
14

15 16 17 18 **CONCLUSIONS**

19
20 In this population-based nested case-control study, no overall association between vitamin D
21 status and risk of LBP was found. The positive association observed in women with blood
22 samples drawn in the winter/spring season needs confirmation from other studies.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Acknowledgements** The Nord-Trøndelag Health Study (the HUNT study) is a collaboration
4 between the HUNT Research Centre, Faculty of Medicine and Health Science, the Norwegian
5 University of Science and Technology (NTNU); Norwegian Institute of Public Health;
6 Central Norway Health Authority; and the Nord-Trøndelag County Council. Laboratory
7 measurements were carried out at facilities owned by the Nord-Trøndelag Hospital Trust.
8
9
10

11
12
13
14 **Contributors** IngridH, IvarH, KH, XMM, AL and JAZ contributed to the study design.
15 IngridH and IvarH contributed to analysis and interpretation of data. IngridH wrote the paper.
16 IvarH, KH, XMM, AL and JAZ all revised the manuscript. All the authors have read and
17 approved the paper.
18
19
20
21
22
23

24 **Funding** Xiao-Mei Mai received funding from the Research Council of Norway for the
25 measurements of vitamin D in the first and second subsamples.
26
27
28
29

30 **Competing interests** None declared.
31
32
33

34 **Ethics approval** The work was approved by the Regional Committee for Medical and Health
35 Research Ethics in Central Norway, and HUNT was also approved by the Norwegian Data
36 Inspectorate. Each participant in the HUNT2 and HUNT3 surveys signed a written informed
37 consent regarding the collection and use of data for research purposes.
38
39
40
41
42
43

44 **Data sharing statement** The data set analysed belongs to a third party, the HUNT study (the
45 Nord-Trøndelag Health Study). The authors of the current manuscript are not affiliated with
46 the project as such, but have been given permission to analyse the data after obtaining the
47 necessary Norwegian permits. Because of the confidentiality requirements according to
48 Norwegian law, a data set of this kind with information from a complete county at the
49 individual level cannot be made public. However, research groups wishing to analyse data
50 from the HUNT study may apply to the HUNT organisation (<http://www.ntnu.edu/hunt>) to get
51 access to the data, after having obtained the permits needed according to Norwegian law.
52
53
54
55
56
57
58
59
60

References

- 1 Lambeek LC, Bosmans JE, Van Royen BJ, et al. Effect of integrated care for sick listed patients with chronic low back pain: Economic evaluation alongside a randomised controlled trial. *BMJ* 2010;341:c6414.
- 2 Maher C, Underwood M, Buchbinder R. Non-specific low back pain. *Lancet* 2017;389:736-47.
- 3 Holick MF. Vitamin D Deficiency. *N Engl J Med* 2007;357:266-81.
- 4 Wintermeyer E, Ihle C, Ehnert S, et al. Crucial role of vitamin D in the musculoskeletal system. *Nutrients* 2016;8:319.
- 5 Straube S, Moore RA, Derry S, et al. Vitamin D and chronic pain. *Pain* 2009;141:10-13.
- 6 Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. *Mayo Clin Proc* 2003;78:1463-70.
- 7 McBeth J, Pye SR, O'Neill TW, et al. Musculoskeletal pain is associated with very low levels of vitamin D in men: results from the European Male Ageing Study. *Ann Rheum Dis* 2010;69:1448-52.
- 8 Hicks GE, Shardell M, Miller RR, et al. Associations between vitamin D status and pain in older adults: the Invecchiare in Chianti Study. *J Am Geriatr Soc* 2008;56:785-91.
- 9 Al Faraj S, Al Mutairi K. Vitamin D deficiency and chronic low back pain in Saudi Arabia. *Spine (Phila Pa 1976)* 2003;28:177-9.
- 10 Kim TH, Lee BH, Lee HM et al. Prevalence of vitamin D deficiency in patients with lumbar spinal stenosis and its relationship with pain. *Pain Physician* 2013;16:165-76.
- 11 Lotfi A, Abdel-Nasser AM, Hamdy A, et al. Hypovitaminosis D in female patients with chronic low back pain. *Clin Rheumatol* 2007;26:1895-901.
- 12 Ghai B, Bansal D, Kapil G, et al. High prevalence of hypovitaminosis D in Indian chronic low back patients. *Pain Physician* 2015;18:E853-62.
- 13 Lodh M, Goswami B, Mahajan RD, et al. Assessment of vitamin D status in patients of chronic low back pain of unknown etiology. *Indian J Clin Biochem* 2015;30:174-9.

1
2
3 14 Heidari B, Shirvani JS, Firouzbahi A, et al. Association between nonspecific skeletal pain
4 and vitamin D deficiency. *Int J Rheum Dis* 2010;13:340-6.
5

6
7 15 Johansen JV, Manniche C, Kjaer P. Vitamin D levels appear to be normal in Danish
8 patients attending secondary care for low back pain and a weak positive correlation between
9 serum level vitamin D and Modic changes was demonstrated: a cross-sectional cohort study
10 of consecutive patients with non-specific low back pain. *BMC Musculoskelet Disord*
11 2013;14:78.
12
13

14
15
16 16 Thörneby A, Nordeman LM, Johanson EH. No association between level of vitamin D and
17 chronic low back pain in Swedish primary care: a cross-sectional case-control study. *Scand J*
18 *Prim Health Care* 2016;34:196-204.
19
20

21
22 17 Alghadir AH, Gabr SA, Al-Eisa ES. Mechanical factors and vitamin D deficiency in
23 schoolchildren with low back pain: biochemical and cross-sectional survey analysis. *J Pain*
24 *Res* 2017;10:855-65.
25
26

27
28 18 Mai XM, Chen Y, Camargo CA Jr, et al. Cross-sectional and prospective cohort study of
29 serum 25-hydroxyvitamin D level and obesity in adults: the HUNT Study. *Am J Epidemiol*
30 2012;175:1029-36.
31
32

33
34 19 Earthman CP, Beckman LM, Masodkar K, et al. The link between obesity and low
35 circulating 25-hydroxyvitamin D concentrations: considerations and implications. *Int J Obes*
36 *(Lond)* 2012;36:387-96.
37
38

39
40 20 Heuch I, Heuch I, Hagen K, et al. Body mass index as a risk factor for developing chronic
41 low back pain: a follow-up in the Nord-Trøndelag Health Study. *Spine (Phila Pa 1976)*
42 2013;38:133-9.
43
44

45
46 21 Larose TL, Chen Y, Camargo CA, et al. Factors associated with vitamin D deficiency in a
47 Norwegian population: the HUNT Study. *J Epidemiol Community Health* 2014;68:165-70.
48

49
50 22 Holick MF. Resurrection of vitamin D deficiency and rickets. *J Clin Invest*
51 2006;116:2062-72.
52

53
54 23 Krokstad S, Langhammer A, Hveem K, et al. Cohort profile: the HUNT Study, Norway.
55 *Int J Epidemiol* 2013;42:968-77.
56
57
58
59
60

- 1
2
3 24 Mai XM, Langhammer A, Camargo CA Jr, et al. Serum 25-hydroxyvitamin D levels and
4 incident asthma in adults: the HUNT Study. *Am J Epidemiol* 2012;176:1169-76.
5
6
7 25 Larose TL, Langhammer A, Chen Y, et al. Serum 25-hydroxyvitamin D levels and lung
8 function in adults with asthma: the HUNT Study. *Eur Respir J* 2015;45:1019-26.
9
10
11 26 Ross AC, Manson JE, Abrams SA, et al. The 2011 dietary reference intakes for calcium
12 and vitamin D: what dietetics practitioners need to know. *J Am Diet Assoc* 2011;111:524-7.
13
14
15 27 Heuch I, Heuch I, Hagen K, et al. Physical activity level at work and risk of chronic low
16 back pain: A follow-up in the Nord-Trøndelag Health Study. *PLOS ONE* 2017;12:e0175086.
17
18
19 28 Heuch I, Heuch I, Hagen K, et al. Is there a U-shaped relationship between physical
20 activity in leisure time and risk of chronic low back pain? The HUNT Study. *BMC Public*
21 *Health* 2016;16:306.
22
23
24
25 29 Holmen J, Midthjell K, Krüger Ø, et al. The Nord-Trøndelag Health Study 1995–97
26 (HUNT 2): objectives, contents, methods and participation. *Norw J Epidemiol* 2003;13:19-32.
27
28
29
30 30 Jorde R, Sneve M, Hutchinson M, et al. Tracking of serum 25-hydroxyvitamin D levels
31 during 14 years in a population-based study and during 12 months in an intervention study.
32 *Am J Epidemiol* 2010;171:903-8.
33
34
35 31 Schramm S, Lahner H, Jöckel KH, et al. Impact of season and different vitamin D
36 thresholds on prevalence of vitamin D deficiency in epidemiological cohorts—a note of
37 caution. *Endocrine* Published Online First: 17 April 2017. doi: 10.1007/s12020-017-1292-7
38
39
40
41 32 Michaëlsson K, Wolk A, Byberg L, et al. The seasonal importance of serum 25-
42 hydroxyvitamin D for bone mineral density in older women. *J Intern Med* 2017;281:167-78.
43
44
45 33 Drake MT. Vitamin D and the goldilocks principle: too little, too much, or just right? *J*
46 *Clin Endocrinol Metab* 2014;99:1164-6.
47
48
49 34 Amrein K, Quraishi SA, Litonjua AA, et al. Evidence for a U-shaped relationship between
50 prehospital vitamin D status and mortality: a cohort study. *J Clin Endocrinol Metab*
51 2014;99:1461-9.
52
53
54
55 35 Vasile M, Corinaldesi C, Antinozzi C, et al. Vitamin D in autoimmune rheumatic diseases:
56 A view inside gender differences. *Pharmacol Res* 2017;117:228-41.
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

36 Datta P, Philipsen PA, Olsen P, et al. The half-life of 25(OH)D after UVB exposure depends on gender and vitamin D receptor polymorphism but mainly on the start level. *Photochem Photobiol Sci* Published Online First: 9 May 2017. doi: 10.1039/c6pp00258g

For peer review only

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any pre-specified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5-6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	12-13
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	5-6

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5-6
		(b) Give reasons for non-participation at each stage	5-6
		(c) Consider use of a flow diagram	5-6
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	6
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	NA
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	8
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	6-7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9-11
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Is there an association between vitamin D status and risk of chronic low back pain? A nested case-control analysis in the Nord-Trøndelag Health Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018521.R1
Article Type:	Research
Date Submitted by the Author:	14-Sep-2017
Complete List of Authors:	Heuch, Ingrid; Oslo University Hospital, Department of Research, Innovation and Education, Division of Clinical Neuroscience Heuch, Ivar; University of Bergen, Department of Mathematics Hagen, Knut; Norwegian University of Science and Technology, Department of Neuroscience; St. Olavs Hospital, Norwegian National Headache Centre, Department of Neurology Mai, Xiao-Mei; Norwegian University of Science and Technology, Department of Public Health and Nursing, Faculty of Medicine and Health Science Langhammer, Arnulf; Norwegian University of Science and Technology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences Zwart, John-Anker; Oslo University Hospital, Department of Research, Innovation and Education, Division of Clinical Neuroscience; University of Oslo, Faculty of Medicine
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Public health
Keywords:	EPIDEMIOLOGY, Vitamin D AND low back, Back pain < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts

Is there an association between vitamin D status and risk of chronic low back pain? A nested case-control analysis in the Nord-Trøndelag Health Study

Ingrid Heuch,¹ Ivar Heuch,² Knut Hagen,^{3,4} Xiao-Mei Mai,⁵ Arnulf Langhammer,⁵ John-Anker Zwart^{1,6}

¹Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway

²Department of Mathematics, University of Bergen, Bergen, Norway

³Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway

⁴Norwegian National Headache Centre, Department of Neurology, St. Olavs Hospital, Trondheim, Norway

⁵Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

⁶Faculty of Medicine, University of Oslo, Oslo, Norway

Correspondence to

Ingrid Heuch, MD, PhD, Department of Research, Innovation and Education, Oslo University Hospital, P.O. Box 4956 Nydalen, N-0424 Oslo, Norway.

E-mail: ingrid.heuch@ous-hf.no

Telephone +4790684232

Word count: 3026

ABSTRACT

Objective: To explore potential associations between vitamin D status and risk of chronic low back pain (LBP) in a Norwegian cohort, and to investigate whether relationships depend on the season of blood sample collection.

Design: A nested case-control study in a prospective data set.

Setting: The Norwegian community-based Nord-Trøndelag Health Study (HUNT). Data were collected in the HUNT2 (1995-1997) and HUNT3 (2006-2008) surveys.

Main outcome measure: Chronic LBP, defined as LBP persisting at least 3 months continuously during the past year.

Participants: Among individuals aged 19-55 years without LBP in HUNT2, a data set was generated including 1685 cases with LBP in HUNT3 and 3137 controls without LBP.

Methods: Blood samples from the participants collected in HUNT2 were analysed for serum 25-hydroxyvitamin D (25(OH)D) level. Associations with LBP in HUNT3 were evaluated by unconditional logistic regression analysis with adjustment for age, sex, work status, physical activity at work and in leisure time, education, smoking and BMI.

Results: No association between vitamin D status and risk of chronic LBP was found in the total data set (OR per 10 nmol/l 25(OH)D =1.01, 95% CI 0.97 to 1.06) or in individuals with blood samples collected in summer/autumn (OR per 10 nmol/l 25(OH)D =0.99, 95% CI 0.93 to 1.06). For blood samples drawn in winter/spring associations differed significantly between women and men ($p=0.004$). Among women a positive association was seen (OR per 10 nmol/l 25(OH)D =1.11, 95% CI 1.02 to 1.20), but among men no significant association was observed (OR per 10 nmol/l 25(OH)D =0.90, 95% CI 0.81 to 1.01).

Conclusions: Overall, no association between vitamin D status and risk of LBP was demonstrated. The association suggested in women for the winter/spring season cannot be regarded as established.

KEYWORDS

back pain, musculoskeletal, vitamin D, epidemiology

Strengths and limitations of this study

-The study is prospective and the medical condition considered, chronic low back pain at end of follow-up, cannot have influenced vitamin D status at baseline.

-Season of blood sample collection for analysis of serum 25(OH)D is taken into account in the analysis.

-Vitamin D and back pain status were not registered in the intermediate period between baseline and end of follow-up.

-The mean length of time between blood sample collection and assessment of final back pain status was 11 years, and individual vitamin D status may have changed considerably in the meantime.

INTRODUCTION

Low back pain (LBP) is one of the most common musculoskeletal disorders and often leads to sick leave and a high degree of disability with substantial costs for society.[1] The causes of non-specific LBP are not sufficiently understood.[2]

Vitamin D is required for absorption of calcium from the intestines, and vitamin D has shown positive health effects on the muscle and skeletal system.[3] Skeletal muscles have vitamin D receptors and may require vitamin D for maximum function.[4] Associations between vitamin D deficiency and incidence of chronic pain have been suggested in various studies, but the evidence is not conclusive.[5] Some studies have found associations between vitamin D deficiency and occurrence of non-specific musculoskeletal pain in patient materials[6] and in population-based data sets.[7] A meta-analysis[8] concluded that vitamin D supplementation can decrease pain scores in chronic widespread pain.

Very few population-based studies have been carried out regarding associations between vitamin D status and occurrence of back pain,[9] in particular with a prospective design. Studies of associations between vitamin D status and back pain have mostly been based on relatively small data sets involving patients, with some studies[10-14] suggesting an association between low vitamin D levels and back pain, while other studies[15-17] were unable to demonstrate any relationships. A cross-sectional study among schoolchildren also indicated such an association.[18] A small randomized clinical trial of patients with chronic LBP failed to show any effect of vitamin D supplementation.[19]

Potential associations between vitamin D deficiency and LBP have partly been ascribed to osteomalacia[12], with an accumulation of osteoid because of defective mineralization. Poor muscle strength induced by vitamin D deficiency[3] may also affect the experience of LBP. It is not certain, however, whether these factors play any role considering the incidence of low back pain at the population level.

Only prospective studies can show whether vitamin D levels affect the subsequent risk of experiencing LBP. It is possible that back pain conversely can affect vitamin D status,[11] perhaps through modified behaviour influencing exposure to sunlight or through nutritional factors, and for this reason it is essential to base conclusions on results from prospective studies. It is important to carry out adjustment for potential confounders such as obesity, which is related to both vitamin D levels and to risk of low back pain.[20-22] Vitamin D

1
2
3 levels are higher after sun exposure, with the prevalence of vitamin D deficiency varying
4 seasonally,[23] so associations should also be assessed separately for the summer/autumn and
5 winter/spring seasons.
6
7

8
9 This study will investigate whether an association can be established between vitamin D
10 status and risk of LBP in a case-control study nested in a Norwegian cohort. Vitamin D status
11 is based on measurement of the major circulating metabolite 25-hydroxyvitamin D
12 (25(OH)D).[24] The importance of seasonality for blood sample collection for vitamin D
13 measurement will be explored.
14
15
16
17
18
19
20

21 **METHODS**

22 **Participants**

23
24
25 The present work is based on information from the Nord-Trøndelag Health Study (HUNT).
26 From 1995 to 1997, the large health survey HUNT2 was conducted in Nord-Trøndelag county
27 in Norway. The entire adult population received a health questionnaire and participants
28 underwent a clinical examination, including measurements of body weight and height.[25] In
29 particular, each participant provided information in the questionnaire showing whether he or
30 she had experienced chronic LBP during the preceding 12 month period, defined as LBP
31 lasting at least three months continuously in that period. Blood samples were drawn at the
32 clinical examination. In the HUNT3 survey, conducted in 2006 to 2008 in the same county
33 with a corresponding target population, similar questionnaires were distributed.[25]
34 Information about residence status was supplied by national registries and linked by use of the
35 unique Norwegian personal identification numbers.
36
37
38
39
40
41
42
43

44
45 A nested case-control study was conducted using prospective data from HUNT2 regarded as
46 baseline and HUNT3 regarded as follow-up, including 4822 individuals in the age range 19-
47 55 years when attending HUNT2. Vitamin D status was assessed on the basis of blood
48 samples from the participants collected in HUNT2 in 1995 to 1997, but the actual
49 measurements were only carried out later. Participants belonged to three different subsamples.
50 The first and second subsample consisted of random samples from HUNT2 and were
51 established in connection with previous studies of the association between vitamin D and
52 asthma and lung function,[26, 27] but in the current study all individuals with LBP in HUNT2
53 were excluded. The first subsample was analysed for 25(OH)D in 2010, and included
54
55
56
57
58
59
60

1
2
3 altogether 1492 persons (figure 1), comprising 247 cases (individuals with LBP in HUNT3)
4 and 1245 controls (individuals without LBP in HUNT3). The second subsample with analysis
5 date for 25(OH)D in 2015 included a total of 2051 persons (figure 1), comprising 343 cases
6 and 1708 controls. The third subsample had measurements of 25(OH)D carried out in
7
8 2014/2015 and consisted of 1279 persons without LBP in HUNT2. Of these, a total of 1095
9
10 cases were selected at random among persons suffering from LBP in HUNT3 and 184
11
12 controls were randomly selected among persons without LBP in HUNT3 (figure 1). The third
13
14 subsample was solely established for the current nested case-control study. None of the
15
16 individuals included in this study had missing values for any covariate considered.
17

18
19 The original plan was that the nested case-control study would consist of the combined first
20
21 and third subsamples only, and the size of the third subsample was adapted to power
22
23 requirements in this data set. The second subsample only became available at a later stage.
24
25
26
27

28 **Exposure**

29
30 Blood samples collected in HUNT2 were stored at -70 °C until analysis. The level of
31
32 25(OH)D in serum was measured in the years 2010 and in 2014/2015 by chemiluminescent
33
34 immunoassay (CLIA) methodology, using Liaison 25-OH Vitamin D Total assay (DiaSorin
35
36 Inc., Saluggia, Italy). The method has an intraassay coefficient of variation of 4% and an
37
38 interassay coefficient of variation of 8%. Another kit from DiaSorin was used from 2014. A
39
40 total of 118 samples with measurements available from 2010 were reanalysed in 2015 with
41
42 the new kit. After exclusion of 2 outliers, a conversion factor for measurements from 2010 to
43
44 new values from 2014/2015 was established by Passing and Bablok regression.[28]

45
46 Serum 25(OH)D levels were classified into three groups <50.0 nmol/l, 50.0-74.9 nmol/l and
47
48 ≥75.0 nmol/l, which are widely used categories in studies of vitamin D levels. Values <50.0
49
50 nmol/l are usually regarded as representing vitamin D deficiency.[29]

51 **Covariate assessment**

52
53
54 Baseline age was categorized into 10-year intervals. Four categories of work status were
55
56 defined, the first comprising people being employed or carrying out professional work. The
57
58
59
60

1
2
3 second category included those temporarily out of work, students and individuals in military
4 service. The third category included pensioners and people receiving social security support,
5 and the fourth category represented women occupied full-time with housework. Those
6 currently working supplied information about physical activity at work,[30] in four categories
7 representing substantially sedentary work, work involving extensive walking, work leading to
8 both walking and lifting, and work involving particularly strenuous activities. For physical
9 activity in leisure time, including going to work, one category included those engaged in light
10 activity only or hard physical activity (leading to sweating or being out of breath) <1 hour per
11 week.[31] Other categories represented hard physical activity 1-2 and ≥ 3 hours per week.

12
13 Education was grouped according to duration as ≤ 9 , 10-12, or ≥ 13 years. Categories of
14 cigarette smoking represented current daily smoking, previous daily smoking and never daily
15 smoking. BMI, defined as weight/height² and computed in kg/m², was subdivided into three
16 groups: <25, 25-29.9, ≥ 30 .

17
18 Season of blood sample collection was categorized as either the summer/autumn season (June
19 through November) or the winter/spring season (December through May). This subdivision
20 gives a marked difference in vitamin D deficiency between 6-months periods.[23]

21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 **Statistical methods**

36 Associations between 25(OH)D levels in serum and risk of chronic LBP were assessed by
37 unconditional logistic regression analysis with adjustment for potential confounders. Analyses
38 were performed separately with 25(OH)D levels as categorical and continuous variables. All
39 other variables were considered categorical. First, adjustments were carried out for age and
40 sex and a factor indicating which subsample each individual belonged to. Additional
41 adjustments for work status, physical activity at work and in leisure time, education, smoking,
42 BMI and season of blood sample collection were then introduced. Separate tests were
43 performed for interaction between continuous 25(OH)D level and all variables adjusted for.
44 Linearity in the association with continuous 25(OH)D level was tested for by adding a
45 quadratic term to the statistical model. All statistical analyses were carried out using IBM
46 SPSS version 23 (IBM Corp., Armonk, New York).

47
48 Separate analyses were limited to participants who had the blood samples drawn in the
49 summer/autumn season and the winter/spring season.

RESULTS

The age distribution was quite similar among cases and controls (table 1). The percentage of women was higher among cases than among controls. Within the three separate groups of serum 25(OH)D levels categorized as <50.0 nmol/l, 50.0-74.9 nmol/l and \geq 75.0 nmol/l, the percentage of persons with and without LBP at end of follow-up were almost the same among cases and controls (table 1).

Table 1 Number of individuals by age, sex, vitamin D status and case-control status

	Cases, with LBP at end of follow-up		Controls, without LBP at end of follow-up	
	Number	Percent	Number	Percent
Age groups (years)				
19-29	246	15	504	16
30-39	492	29	951	30
40-49	687	41	1191	38
50-55	260	15	491	16
Sex				
Female	1043	62	1677	54
Male	642	38	1460	47
25(OH)D (nmol/l)				
<50.0	925	55	1689	54
50.0-74.9	619	37	1126	36
\geq 75.0	141	8	322	10

LBP, low back pain.

Table 2 Descriptive statistics of 25(OH)D level by case-control status

	Cases, with LBP at end of follow-up				Controls, without LBP at end of follow-up			
	Number	Mean (nmol/l)	SD (nmol/l)	Median (nmol/l)	Number	Mean (nmol/l)	SD (nmol/l)	Median (nmol/l)
Total data set								
All seasons	1685	49.4	18.2	47.9	3137	50.0	19.1	48.0
Summer/autumn	773	54.1	18.4	52.0	1424	56.7	19.0	55.2
Winter/spring	912	45.4	17.0	43.8	1713	44.4	17.4	41.9
Women								
All seasons	1043	50.2	18.6	48.9	1677	50.5	19.0	49.0
Summer/autumn	480	53.8	18.7	52.9	784	56.2	18.7	54.4
Winter/spring	563	47.1	17.9	45.9	893	45.4	17.9	43.0
Men								
All seasons	642	48.0	17.4	45.8	1460	49.4	19.3	46.6
Summer/autumn	293	54.5	18.0	51.3	640	57.4	19.4	56.1
Winter/spring	349	42.6	14.9	40.8	820	43.2	16.7	40.4

LBP, low back pain; SD, standard deviation.

In the total data set, the mean serum 25(OH)D levels were quite similar among cases and controls (table 2). Both in women and men the serum 25(OH)D levels were higher in the summer/autumn than in the winter/spring season among cases and controls.

In the overall data set no association was found between vitamin D status and risk of LBP, neither with adjustment for age, sex and subsample nor with complete adjustment (OR per 10 nmol/l 25(OH)D= 1.01, 95% CI 0.97 to 1.06) (table 3). No significant interaction was found, but the interaction with sex was marginally significant (p=0.06). A weak positive association was suggested among women, although the estimated relation among men was in the opposite direction (table 3). Results did not differ significantly between subsamples.

Table 3 Associations between vitamin D status and risk of chronic LBP

	With adjustment for age, sex and subsample		With complete adjustment*	
	OR (95% CI)	p	OR (95% CI)	p
Total data set				
25(OH)D (nmol/l)		0.64 [†]		0.97 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	0.94 (0.80 to 1.11)		1.01 (0.85 to 1.20)	
≥75.0	0.90 (0.68 to 1.18)		0.98 (0.73 to 1.31)	
Per 10 nmol/l	0.99 (0.95 to 1.03)	0.59	1.01 (0.97 to 1.06)	0.59
Women				
25(OH)D (nmol/l)		0.54 [†]		0.27 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	1.09 (0.88 to 1.36)		1.20 (0.96 to 1.51)	
≥75.0	0.91 (0.64 to 1.30)		1.05 (0.72 to 1.52)	
Per 10 nmol/l	1.02 (0.97 to 1.08)	0.48	1.06 (1.00 to 1.12)	0.054
Men				
25(OH)D (nmol/l)		0.10 [†]		0.16 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	0.75 (0.57 to 0.98)		0.76 (0.57 to 1.01)	
≥75.0	0.90 (0.58 to 1.39)		0.88 (0.55 to 1.41)	
Per 10 nmol/l	0.94 (0.88 to 1.01)	0.10	0.94 (0.88 to 1.02)	0.13

*Adjustment for age, sex, work status, physical activity at work and in leisure time, education, smoking, BMI, subsample and season of blood sample collection.

[†]For categorical effect.

LBP, low back pain; OR, odds ratio; CI, confidence interval; BMI, body mass index.

Separate analyses of the association between vitamin D status and risk of LBP by season of blood sample collection revealed no effect in either sex in the summer/autumn season (table 4). However, in the winter/spring season associations differed significantly between women and men (p=0.004). In women a significant positive association was observed (OR per 10 nmol/l 25(OH)D =1.11, 95% CI 1.02 to 1.20) (table 4). In men the estimated association was

negative (OR per 10 nmol/l 25(OH)D =0.90, 95% CI 0.81 to 1.01) but did not reach statistical significance. Considering the different OR values from the categorical analyses, a consistent trend was suggested in each sex.

No significant deviations from linearity were observed in the relationships with 25(OH)D considered as a continuous variable.

Table 4 Associations between vitamin D status and risk of chronic LBP by season of blood sample collection*

	Summer/autumn		Winter/spring	
	OR (95% CI)	p	OR (95% CI)	p
Total data set				
25(OH)D (nmol/l)		0.87 [†]		0.79 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	0.93 (0.72 to 1.20)		1.08 (0.85 to 1.38)	
≥75.0	0.96 (0.66 to 1.39)		0.96 (0.58 to 1.58)	
Per 10 nmol/l	0.99 (0.93 to 1.06)	0.78	1.03 (0.97 to 1.10)	0.37
Women				
25(OH)D (nmol/l)		0.56 [†]		0.27 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	1.13 (0.81 to 1.57)		1.26 (0.92 to 1.73)	
≥75.0	0.89 (0.53 to 1.47)		1.34 (0.76 to 2.35)	
Per 10 nmol/l	1.00 (0.92 to 1.09)	0.94	1.11 (1.02 to 1.20)	0.012
Men				
25(OH)D (nmol/l)		0.15 [†]		0.20 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	0.70 (0.46 to 1.05)		0.84 (0.56 to 1.27)	
≥75.0	1.01 (0.58 to 1.76)		0.37 (0.12 to 1.17)	
Per 10 nmol/l	0.97 (0.88 to 1.08)	0.58	0.90 (0.81 to 1.01)	0.08

*Adjustment for age, sex, work status, physical activity at work and in leisure time, education, smoking, BMI and subsample.

[†]For categorical effect.

LBP, low back pain; OR, odds ratio; CI, confidence interval; BMI, body mass index.

DISCUSSION

The association between vitamin D status and chronic LBP was examined in a case-control study nested in a population-based follow-up of a Norwegian cohort. No association between vitamin D status and risk of LBP was found overall. For measurements in the winter/spring season, associations differed significantly between women and men. Among women a positive association was seen, but among men no significant association was observed.

A strength of the study is that the overwhelming majority of participants belonged to a homogeneous ethnic group.[32] Information was available on potential confounders, which made it possible to carry out accurate adjustments. The risk factor considered is represented by the vitamin D status measured in blood samples drawn at the clinical examination in HUNT2. However, the blood samples were stored for many years at low temperature, and the measurements of serum 25(OH)D levels were carried out in 2010 or in 2014/2015. Despite attempts to standardize the measurements, use of different instruments in the two periods may have led to minor systematic deviations in the 25(OH)D levels. To some extent, this was accounted for by adjusting all statistical analyses for subsample. This procedure was also essential in view of the different sampling procedures applied to establish the subsamples. The Liaison immunoassay method may still underestimate true 25(OH)D levels[33] and a direct comparison with values found by other methods may not be justified.[34]

A limitation is the lack of information about back pain occurring at other times in the 11-year follow-up interval between HUNT2 and HUNT3. The case definition only refers to the last year before collection of information in HUNT3. Thus all cases must have experienced incident chronic LBP during follow-up but so may some of the controls in the intervening period if they later recovered. Any real association between vitamin D status and LBP should be present anyhow but may be more difficult to detect. Furthermore, the extent of back pain was not characterized by the participants.

Another potential problem is the relatively long period between collection of information about risk factors and the recording of LBP status. In view of the weaker associations seen between 25(OH)D levels and mortality and cancer risk in prospective studies with longer follow-periods, it has been suggested that 25(OH)D levels should be measured at regular

1
2
3 intervals in prospective studies, perhaps every 2-4 years.[35] Such information was not
4 available in the present study. However, vitamin D levels have been shown to be relatively
5 stable over periods as long as 14 years in the Norwegian population,[36] and large data sets in
6 other countries have shown a definite degree of stability over somewhat shorter periods.[37,
7 38] In data with measurements from the HUNT2 survey, low 25(OH)D levels showed a clear
8 association with all-cause mortality in a prospective study with a median follow-up time of
9 18.5 years.[39] Thus potential relationships between 25(OH)D levels and disease should still
10 persist in a study such as the current one with 11 years of follow-up, although associations
11 may be attenuated. The state of relevant confounders may also change during a long follow-
12 up. An alternative to the design used here would be a cross-sectional case-control study based
13 on both 25(OH)D levels and reports of chronic LBP from the HUNT2 survey. Problems
14 concerning 25(OH)D levels changing over time would be eliminated but it would not be
15 possible to rule out an influence of disease on 25(OH)D status.
16
17
18
19
20
21
22
23
24

25 There are few population-based studies of relationships between vitamin D status and LBP.[9]
26 Some studies have investigated such relationships among patients,[11, 13, 16] but population-
27 based studies of risk of LBP with a prospective design have been lacking. The present study is
28 to our knowledge the only prospective study of the association between vitamin D status and
29 risk of LBP.
30
31
32
33

34 In cross-sectional population-based studies, an association between low level of 25(OH)D and
35 prevalence of back pain has been found in older women[9] and in schoolchildren.[18] Some
36 case-control studies have shown an association between low levels of vitamin D and
37 occurrence of back pain,[12, 14] but others do not support an association.[15, 17] In a recent
38 small Swedish case-control study no difference in vitamin D levels could be established
39 between participants with chronic LBP and matched controls.[17] This is consistent with the
40 overall results found in our study.
41
42
43
44
45

46 Among women with blood samples drawn in the winter/spring season, we found that high
47 levels of vitamin D were associated with an increased risk of LBP, which is the opposite of
48 what was initially hypothesized. In a Danish cross-sectional study of LBP patients an
49 association in the same direction was found, and normal levels of vitamin D, as opposed to
50 vitamin D deficiency, were associated with more Modic changes in the lumbar vertebral end
51 plates as seen on MRI.[16]
52
53
54
55
56
57
58
59
60

1
2
3 An association between vitamin D deficiency and adiposity has been found in several
4 studies.[21] This was also confirmed in a cross-sectional study in the HUNT population.[23]
5
6 In a prospective study using data from HUNT2 and HUNT3, overweight and obesity were
7
8 found to be associated with a predisposition to chronic LBP.[22] This suggests that BMI
9
10 could be a confounder in the association with 25(OH)D. However, our complete analyses
11
12 included adjustment for BMI, and it is not to be expected that any substantial relationship
13
14 should remain because of the association with adiposity.

15
16 In view of the seasonal variation in sun exposure, it is important to look at the time when
17
18 blood samples are collected to define vitamin D deficiency.[40] Thus in a study of bone
19
20 mineral density the summer season was found to be the best period to determine the serum
21
22 25(OH)D level.[41] This contrasts with our results, with a positive association between LBP
23
24 and vitamin D status observed in the winter/spring season for women only. Elevated levels of
25
26 25(OH)D may be harmful in other respects.[42] In a study of mortality among hospitalized
27
28 patients a U-shaped relationship was found, with both low and high values of 25(OH)D
29
30 associated with increased mortality.[42, 43] However, the 25(OH)D levels had to be
31
32 considerably above the typical values in the present study to be associated with higher
33
34 mortality and a causal relationship was not inferred, so such effects at the upper end of the
35
36 range for 25(OH)D are hardly relevant here.

37
38 Gender and sex hormone levels are important variables that can influence a possible effect of
39
40 vitamin D in rheumatic diseases.[44] In a Danish population receiving UVB treatment, the
41
42 decline in 25(OH)D varied over time between sexes, with women maintaining a greater half-
43
44 life of 25(OH)D.[45] It is not evident, however, how such differences can explain the sex
45
46 contrast seen in the present study in the association with risk of LBP.

47
48 Measurements of 25(OH)D levels made during the winter/spring season may possibly capture
49
50 variability of vitamin D in a better way, because vitamin D values in winter are not so
51
52 dependent on sunlight exposure. It is possible, however, that women tending to report LBP in
53
54 this population are particularly health-conscious and use more vitamin D supplements during
55
56 the winter/spring season, creating a false positive association. Cod liver oil supplement has
57
58 traditionally represented a major source of vitamin D in Norway,[46] with about 35% of both
59
60 the male and female populations using such supplement in the 1990s.[47] Whole-year usage
among females is associated with poor perceived health but is otherwise associated with a
healthy diet,[46] suggesting that use of supplements is not in general matched to the vitamin

1
2
3 D needs.[46] In any case, the significant relationship observed among women may be
4 spurious due to the multiple statistical tests carried out. Thus this association cannot yet be
5 regarded as causal.
6
7
8
9

10 11 **CONCLUSIONS**

12
13 In this population-based nested case-control study, no overall association between vitamin D
14 status and risk of LBP was found. The positive association observed in women with blood
15 samples drawn in the winter/spring season needs confirmation from other studies.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Acknowledgements** The Nord-Trøndelag Health Study (the HUNT study) is a collaboration
4 between the HUNT Research Centre, Faculty of Medicine and Health Science, the Norwegian
5 University of Science and Technology (NTNU); Norwegian Institute of Public Health;
6 Central Norway Health Authority; and the Nord-Trøndelag County Council. Laboratory
7 measurements were carried out at facilities owned by the Nord-Trøndelag Hospital Trust.
8
9
10

11
12
13
14 **Contributors** IngridH, IvarH, KH, XMM, AL and JAZ contributed to the study design.
15 IngridH and IvarH contributed to analysis and interpretation of data. IngridH wrote the paper.
16 IvarH, KH, XMM, AL and JAZ all revised the manuscript. All the authors have read and
17 approved the paper.
18
19
20
21

22
23
24 **Funding** Xiao-Mei Mai received funding from the Research Council of Norway for the
25 measurements of vitamin D in the first and second subsamples.
26
27
28

29
30 **Competing interests** None declared.
31
32

33
34
35 **Ethics approval** The work was approved by the Regional Committee for Medical and Health
36 Research Ethics in Central Norway, and HUNT was also approved by the Norwegian Data
37 Inspectorate. Each participant in the HUNT2 and HUNT3 surveys signed a written informed
38 consent regarding the collection and use of data for research purposes.
39
40
41

42
43
44 **Data sharing statement** The data set analysed belongs to a third party, the HUNT study (the
45 Nord-Trøndelag Health Study). The authors of the current manuscript are not affiliated with
46 the project as such, but have been given permission to analyse the data after obtaining the
47 necessary Norwegian permits. Because of the confidentiality requirements according to
48 Norwegian law, a data set of this kind with information from a complete county at the
49 individual level cannot be made public. However, research groups wishing to analyse data
50 from the HUNT study may apply to the HUNT organisation (<http://www.ntnu.edu/hunt>) to get
51 access to the data, after having obtained the permits needed according to Norwegian law.
52
53
54
55
56
57
58
59
60

References

- 1 Lambeek LC, Bosmans JE, Van Royen BJ, et al. Effect of integrated care for sick listed patients with chronic low back pain: Economic evaluation alongside a randomised controlled trial. *BMJ* 2010;341:c6414.
- 2 Maher C, Underwood M, Buchbinder R. Non-specific low back pain. *Lancet* 2017;389:736-47.
- 3 Holick MF. Vitamin D Deficiency. *N Engl J Med* 2007;357:266-81.
- 4 Wintermeyer E, Ihle C, Ehnert S, et al. Crucial role of vitamin D in the musculoskeletal system. *Nutrients* 2016;8:319.
- 5 Straube S, Moore RA, Derry S, et al. Vitamin D and chronic pain. *Pain* 2009;141:10-13.
- 6 Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. *Mayo Clin Proc* 2003;78:1463-70.
- 7 McBeth J, Pye SR, O'Neill TW, et al. Musculoskeletal pain is associated with very low levels of vitamin D in men: results from the European Male Ageing Study. *Ann Rheum Dis* 2010;69:1448-52.
- 8 Yong WC, Sanguaneko A, Upala S. Effect of vitamin D supplementation in chronic widespread pain: a systematic review and meta-analysis. *Clin Rheumatol* Published Online First: 15 Aug 2017. doi: 10.1007/s10067-017-3754-y
- 9 Hicks GE, Shardell M, Miller RR, et al. Associations between vitamin D status and pain in older adults: the Invecchiare in Chianti Study. *J Am Geriatr Soc* 2008;56:785-91.
- 10 Al Faraj S, Al Mutairi K. Vitamin D deficiency and chronic low back pain in Saudi Arabia. *Spine (Phila Pa 1976)* 2003;28:177-9.
- 11 Kim TH, Lee BH, Lee HM et al. Prevalence of vitamin D deficiency in patients with lumbar spinal stenosis and its relationship with pain. *Pain Physician* 2013;16:165-76.
- 12 Lotfi A, Abdel-Nasser AM, Hamdy A, et al. Hypovitaminosis D in female patients with chronic low back pain. *Clin Rheumatol* 2007;26:1895-901.

1
2
3 13 Ghai B, Bansal D, Kapil G, et al. High prevalence of hypovitaminosis D in Indian chronic
4 low back patients. *Pain Physician* 2015;18:E853-62.

5
6
7 14 Lodh M, Goswami B, Mahajan RD, et al. Assessment of vitamin D status in patients of
8 chronic low back pain of unknown etiology. *Indian J Clin Biochem* 2015;30:174-9.

9
10
11 15 Heidari B, Shirvani JS, Firouzjahi A, et al. Association between nonspecific skeletal pain
12 and vitamin D deficiency. *Int J Rheum Dis* 2010;13:340-6.

13
14
15 16 Johansen JV, Manniche C, Kjaer P. Vitamin D levels appear to be normal in Danish
16 patients attending secondary care for low back pain and a weak positive correlation between
17 serum level vitamin D and Modic changes was demonstrated: a cross-sectional cohort study
18 of consecutive patients with non-specific low back pain. *BMC Musculoskelet Disord*
19 2013;14:78.

20
21
22 23 17 Thörneby A, Nordeman LM, Johanson EH. No association between level of vitamin D and
24 chronic low back pain in Swedish primary care: a cross-sectional case-control study. *Scand J*
25 *Prim Health Care* 2016;34:196-204.

26
27
28 29 18 Alghadir AH, Gabr SA, Al-Eisa ES. Mechanical factors and vitamin D deficiency in
30 schoolchildren with low back pain: biochemical and cross-sectional survey analysis. *J Pain*
31 *Res* 2017;10:855-65.

32
33
34 35 19 Sandoughi M, Zakeri Z, Mirhosainee Z, et al. The effect of vitamin D on nonspecific low
36 back pain. *Int J Rheum Dis* 2015;18:854-8.

37
38
39 40 20 Mai XM, Chen Y, Camargo CA Jr, et al. Cross-sectional and prospective cohort study of
41 serum 25-hydroxyvitamin D level and obesity in adults: the HUNT Study. *Am J Epidemiol*
42 2012;175:1029-36.

43
44
45 46 21 Earthman CP, Beckman LM, Masodkar K, et al. The link between obesity and low
47 circulating 25-hydroxyvitamin D concentrations: considerations and implications. *Int J Obes*
48 *(Lond)* 2012;36:387-96.

49
50
51 52 22 Heuch I, Heuch I, Hagen K, et al. Body mass index as a risk factor for developing chronic
53 low back pain: a follow-up in the Nord-Trøndelag Health Study. *Spine (Phila Pa 1976)*
54 2013;38:133-9.

- 1
2
3 23 Larose TL, Chen Y, Camargo CA, et al. Factors associated with vitamin D deficiency in a
4 Norwegian population: the HUNT Study. *J Epidemiol Community Health* 2014;68:165-70.
5
6
7 24 Holick MF. Resurrection of vitamin D deficiency and rickets. *J Clin Invest*
8
9 2006;116:2062-72.
10
11 25 Krokstad S, Langhammer A, Hveem K, et al. Cohort profile: the HUNT Study, Norway.
12
13 *Int J Epidemiol* 2013;42:968-77.
14
15 26 Mai XM, Langhammer A, Camargo CA Jr, et al. Serum 25-hydroxyvitamin D levels and
16 incident asthma in adults: the HUNT Study. *Am J Epidemiol* 2012;176:1169-76.
17
18
19 27 Larose TL, Langhammer A, Chen Y, et al. Serum 25-hydroxyvitamin D levels and lung
20 function in adults with asthma: the HUNT Study. *Eur Respir J* 2015;45:1019-26.
21
22
23 28 Passing H, Bablok W. A new biometrical procedure for testing the equality of
24 measurements from two different analytical methods. Application of linear regression
25 procedures for method comparison studies in clinical chemistry, part I. *J Clin Chem Clin*
26
27 *Biochem* 1983;21:709-20.
28
29
30
31 29 Ross AC, Manson JE, Abrams SA, et al. The 2011 dietary reference intakes for calcium
32 and vitamin D: what dietetics practitioners need to know. *J Am Diet Assoc* 2011;111:524-7.
33
34
35 30 Heuch I, Heuch I, Hagen K, et al. Physical activity level at work and risk of chronic low
36 back pain: A follow-up in the Nord-Trøndelag Health Study. *PLoS One* 2017;12:e0175086.
37
38
39 31 Heuch I, Heuch I, Hagen K, et al. Is there a U-shaped relationship between physical
40 activity in leisure time and risk of chronic low back pain? A follow-up in the HUNT Study.
41
42 *BMC Public Health* 2016;16:306.
43
44
45 32 Holmen J, Midthjell K, Krüger Ø, et al. The Nord-Trøndelag Health Study 1995–97
46 (HUNT 2): objectives, contents, methods and participation. *Nor Epidemiol* 2003;13:19-32.
47
48
49 33 Schöttker B, Jansen EH, Haug U, et al. Standardization of misleading immunoassay based
50 25-hydroxyvitamin D levels with liquid chromatography tandem-mass spectrometry in a large
51 cohort study. *PLoS One* 2012;7:e48774.
52
53
54
55
56
57
58
59
60

- 1
2
3 34 Carter GD, Berry J, Durazo-Arvizu R, et al. Hydroxyvitamin D assays: An historical
4 perspective from DEQAS. *J Steroid Biochem Mol Biol* Published Online First: 20 Jul 2017.
5 doi: 10.1016/j.jsbmb.2017.07.018
6
7
8
9 35 Grant WB. Effect of follow-up time on the relation between prediagnostic serum 25-
10 hydroxyvitamin D and all-cause mortality rate. *Dermatoendocrinol* 2012;4:198-202.
11
12
13 36 Jorde R, Sneve M, Hutchinson M, et al. Tracking of serum 25-hydroxyvitamin D levels
14 during 14 years in a population-based study and during 12 months in an intervention study.
15 *Am J Epidemiol* 2010;171:903-8.
16
17
18 37 Saliba W, Barnett O, Stein N, et al. The longitudinal variability of serum 25(OH)D levels.
19 *Eur J Intern Med* 2012;23:e106-11.
20
21
22
23 38 Schöttker B, Haug U, Schomburg L, et al. Strong associations of 25-hydroxyvitamin D
24 concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a
25 large cohort study. *Am J Clin Nutr* 2013;97:782-93.
26
27
28
29 39 Sun YQ, Langhammer A, Skorpen F, et al. Serum 25-hydroxyvitamin D level, chronic
30 diseases and all-cause mortality in a population-based prospective cohort: the HUNT Study,
31 Norway. *BMJ Open* 2017;7:e017256.
32
33
34 40 Schramm S, Lahner H, Jöckel KH, et al. Impact of season and different vitamin D
35 thresholds on prevalence of vitamin D deficiency in epidemiological cohorts—a note of
36 caution. *Endocrine* 2017;56:658-66.
37
38
39
40 41 Michaëlsson K, Wolk A, Byberg L, et al. The seasonal importance of serum 25-
41 hydroxyvitamin D for bone mineral density in older women. *J Intern Med* 2017;281:167-78.
42
43
44 42 Drake MT. Vitamin D and the goldilocks principle: too little, too much, or just right? *J*
45 *Clin Endocrinol Metab* 2014;99:1164-6.
46
47
48
49 43 Amrein K, Quraishi SA, Litonjua AA, et al. Evidence for a U-shaped relationship between
50 prehospital vitamin D status and mortality: a cohort study. *J Clin Endocrinol Metab*
51 2014;99:1461-9.
52
53
54 44 Vasile M, Corinaldesi C, Antinozzi C, et al. Vitamin D in autoimmune rheumatic diseases:
55 A view inside gender differences. *Pharmacol Res* 2017;117:228-41.
56
57
58
59
60

1
2
3 45 Datta P, Philipsen PA, Olsen P, et al. The half-life of 25(OH)D after UVB exposure
4 depends on gender and vitamin D receptor polymorphism but mainly on the start level.
5
6 *Photochem Photobiol Sci* 2017;16:985-95.
7

8
9 46 Brustad M, Braaten T, Lund E. Predictors for cod-liver oil supplement use--the Norwegian
10 Women and Cancer Study. *Eur J Clin Nutr* 2004;58:128-36.
11

12
13 47. Alexander J, Frøyland L, Hemre GI, et al. A comprehensive assessment of fish and other
14 seafood in the Norwegian diet. Oslo: Norwegian Scientific Committee for Food Safety 2006.
15
16

17
18
19
20
21 **Figure legend**
22

23
24 **Figure 1** Flow chart showing participants for statistical analysis in the nested case-control
25 study.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 Flow chart showing participants for statistical analysis in the nested case-control study.

254x338mm (300 x 300 DPI)

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any pre-specified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5-6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	12-13
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	5-6

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5-6
		(b) Give reasons for non-participation at each stage	5-6
		(c) Consider use of a flow diagram	5-6
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	6
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	NA
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	8
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	6-7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9-11
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Is there an association between vitamin D status and risk of chronic low back pain? A nested case-control analysis in the Nord-Trøndelag Health Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018521.R2
Article Type:	Research
Date Submitted by the Author:	04-Oct-2017
Complete List of Authors:	Heuch, Ingrid; Oslo University Hospital, Department of Research, Innovation and Education, Division of Clinical Neuroscience Heuch, Ivar; University of Bergen, Department of Mathematics Hagen, Knut; Norwegian University of Science and Technology, Department of Neuroscience; St. Olavs Hospital, Norwegian National Headache Centre, Department of Neurology Mai, Xiao-Mei; Norwegian University of Science and Technology, Department of Public Health and Nursing, Faculty of Medicine and Health Science Langhammer, Arnulf; Norwegian University of Science and Technology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences Zwart, John-Anker; Oslo University Hospital, Department of Research, Innovation and Education, Division of Clinical Neuroscience; University of Oslo, Faculty of Medicine
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Public health
Keywords:	EPIDEMIOLOGY, Vitamin D AND low back, Back pain < ORTHOPAEDIC & TRAUMA SURGERY

SCHOLARONE™
Manuscripts

Is there an association between vitamin D status and risk of chronic low back pain? A nested case-control analysis in the Nord-Trøndelag Health Study

Ingrid Heuch,¹ Ivar Heuch,² Knut Hagen,^{3,4} Xiao-Mei Mai,⁵ Arnulf Langhammer,⁵ John-Anker Zwart^{1,6}

¹Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway

²Department of Mathematics, University of Bergen, Bergen, Norway

³Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway

⁴Norwegian National Headache Centre, Department of Neurology, St. Olavs Hospital, Trondheim, Norway

⁵Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

⁶Faculty of Medicine, University of Oslo, Oslo, Norway

Correspondence to

Ingrid Heuch, MD, PhD, Department of Research, Innovation and Education, Oslo University Hospital, P.O. Box 4956 Nydalen, N-0424 Oslo, Norway.

E-mail: ingrid.heuch@ous-hf.no

Telephone +4790684232

Word count: 3152

ABSTRACT

Objective: To explore potential associations between vitamin D status and risk of chronic low back pain (LBP) in a Norwegian cohort, and to investigate whether relationships depend on the season of blood sample collection.

Design: A nested case-control study in a prospective data set.

Setting: The Norwegian community-based Nord-Trøndelag Health Study (HUNT). Data were collected in the HUNT2 (1995-1997) and HUNT3 (2006-2008) surveys.

Main outcome measure: Chronic LBP, defined as LBP persisting at least 3 months continuously during the past year.

Participants: Among individuals aged 19-55 years without LBP in HUNT2, a data set was generated including 1685 cases with LBP in HUNT3 and 3137 controls without LBP.

Methods: Blood samples from the participants collected in HUNT2 were analysed for serum 25-hydroxyvitamin D (25(OH)D) level. Associations with LBP in HUNT3 were evaluated by unconditional logistic regression analysis with adjustment for age, sex, work status, physical activity at work and in leisure time, education, smoking and BMI.

Results: No association between vitamin D status and risk of chronic LBP was found in the total data set (OR per 10 nmol/l 25(OH)D =1.01, 95% CI 0.97 to 1.06) or in individuals with blood samples collected in summer/autumn (OR per 10 nmol/l 25(OH)D =0.99, 95% CI 0.93 to 1.06). For blood samples drawn in winter/spring associations differed significantly between women and men ($p=0.004$). Among women a positive association was seen (OR per 10 nmol/l 25(OH)D =1.11, 95% CI 1.02 to 1.20), but among men no significant association was observed (OR per 10 nmol/l 25(OH)D =0.90, 95% CI 0.81 to 1.01).

Conclusions: Overall, no association between vitamin D status and risk of LBP was demonstrated. The association suggested in women for the winter/spring season cannot be regarded as established.

KEYWORDS

back pain, musculoskeletal, vitamin D, epidemiology

Strengths and limitations of this study

-The study is prospective and the medical condition considered, chronic low back pain at end of follow-up, cannot have influenced vitamin D status at baseline.

-Season of blood sample collection for analysis of serum 25(OH)D is taken into account in the analysis.

-Vitamin D and back pain status were not registered in the intermediate period between baseline and end of follow-up.

-The mean length of time between blood sample collection and assessment of final back pain status was 11 years, and individual vitamin D status may have changed considerably in the meantime.

INTRODUCTION

Low back pain (LBP) is one of the most common musculoskeletal disorders and often leads to sick leave and a high degree of disability with substantial costs for society.[1] The causes of non-specific LBP are not sufficiently understood.[2]

Vitamin D is required for absorption of calcium from the intestines, and vitamin D has shown positive health effects on the muscle and skeletal system.[3] Skeletal muscles have vitamin D receptors and may require vitamin D for maximum function.[4] Associations between vitamin D deficiency and incidence of chronic pain have been suggested in various studies, but the evidence is not conclusive.[5] Some studies have found associations between vitamin D deficiency and occurrence of non-specific musculoskeletal pain in patient materials[6] and in population-based data sets.[7] A meta-analysis[8] concluded that vitamin D supplementation can decrease pain scores in chronic widespread pain.

Very few population-based studies have been carried out regarding associations between vitamin D status and occurrence of back pain,[9] in particular with a prospective design. Studies of associations between vitamin D status and back pain have mostly been based on relatively small data sets involving patients, with some studies[10-14] suggesting an association between low vitamin D levels and back pain, while other studies[15-17] were unable to demonstrate any relationships. A cross-sectional study among schoolchildren also indicated such an association.[18] A small randomized clinical trial of patients with chronic LBP failed to show any effect of vitamin D supplementation.[19]

Potential associations between vitamin D deficiency and LBP have partly been ascribed to osteomalacia[12], with an accumulation of osteoid because of defective mineralization. Poor muscle strength induced by vitamin D deficiency[3] may also affect the experience of LBP. It is not certain, however, whether these factors play any role considering the incidence of low back pain at the population level.

Only prospective studies can show whether vitamin D levels affect the subsequent risk of experiencing LBP. It is possible that back pain conversely can affect vitamin D status,[11] perhaps through modified behaviour influencing exposure to sunlight or through nutritional factors, and for this reason it is essential to base conclusions on results from prospective studies. It is important to carry out adjustment for potential confounders such as obesity, which is related to both vitamin D levels and to risk of low back pain.[20-22] Vitamin D

1
2
3 levels are higher after sun exposure, with the prevalence of vitamin D deficiency varying
4 seasonally,[23] so associations should also be assessed separately for the summer/autumn and
5 winter/spring seasons.
6
7

8
9 This study will investigate whether an association can be established between vitamin D
10 status and risk of LBP in a case-control study nested in a Norwegian cohort. Vitamin D status
11 is based on measurement of the major circulating metabolite 25-hydroxyvitamin D
12 (25(OH)D).[24] The importance of seasonality for blood sample collection for vitamin D
13 measurement will be explored.
14
15
16
17
18
19
20

21 **METHODS**

22 **Participants**

23
24
25 The present work is based on information from the Nord-Trøndelag Health Study (HUNT).
26 From 1995 to 1997, the large health survey HUNT2 was conducted in Nord-Trøndelag county
27 in Norway. The entire adult population received a health questionnaire and participants
28 underwent a clinical examination, including measurements of body weight and height.[25] In
29 particular, each participant provided information in the questionnaire showing whether he or
30 she had experienced chronic LBP during the preceding 12 month period, defined as LBP
31 lasting at least three months continuously in that period. Blood samples were drawn at the
32 clinical examination. In the HUNT3 survey, conducted in 2006 to 2008 in the same county
33 with a corresponding target population, similar questionnaires were distributed.[25]
34 Information about residence status was supplied by national registries and linked by use of the
35 unique Norwegian personal identification numbers.
36
37
38
39
40
41
42
43

44
45 A nested case-control study was conducted using prospective data from HUNT2 regarded as
46 baseline and HUNT3 regarded as follow-up, including 4822 individuals in the age range 19-
47 55 years when attending HUNT2. Vitamin D status was assessed on the basis of blood
48 samples from the participants collected in HUNT2 in 1995 to 1997, but the actual
49 measurements were only carried out later. Participants belonged to three different subsamples.
50 The first and second subsample consisted of random samples from HUNT2 and were
51 established in connection with previous studies of the association between vitamin D and
52 asthma and lung function,[26, 27] but in the current study all individuals with LBP in HUNT2
53 were excluded. The first subsample was analysed for 25(OH)D in 2010, and included
54
55
56
57
58
59
60

1
2
3 altogether 1492 persons (figure 1), comprising 247 cases (individuals with LBP in HUNT3)
4 and 1245 controls (individuals without LBP in HUNT3). The second subsample with analysis
5 date for 25(OH)D in 2015 included a total of 2051 persons (figure 1), comprising 343 cases
6 and 1708 controls. The third subsample had measurements of 25(OH)D carried out in
7
8 2014/2015 and consisted of 1279 persons without LBP in HUNT2. Of these, a total of 1095
9
10 cases were selected at random among persons suffering from LBP in HUNT3 and 184
11
12 controls were randomly selected among persons without LBP in HUNT3 (figure 1). The third
13
14 subsample was solely established for the current nested case-control study. None of the
15
16 individuals included in this study had missing values for any covariate considered.
17

18
19 The original plan was that the nested case-control study would consist of the combined first
20
21 and third subsamples only, and the size of the third subsample was adapted to power
22
23 requirements in this data set. The second subsample only became available at a later stage.
24
25
26
27

28 **Exposure**

29
30 Blood samples collected in HUNT2 were stored at -70 °C until analysis. The level of
31
32 25(OH)D in serum was measured in the years 2010 and in 2014/2015 by chemiluminescent
33
34 immunoassay (CLIA) methodology, using Liaison 25-OH Vitamin D Total assay (DiaSorin
35
36 Inc., Saluggia, Italy). The method has an intraassay coefficient of variation of 4% and an
37
38 interassay coefficient of variation of 8%. Another kit from DiaSorin was used from 2014. A
39
40 total of 118 samples with measurements available from 2010 were reanalysed in 2015 with
41
42 the new kit. After exclusion of 2 outliers, a conversion factor for measurements from 2010 to
43
44 new values from 2014/2015 was established by Passing and Bablok regression.[28]

45
46 Serum 25(OH)D levels were classified into three groups <50.0 nmol/l, 50.0-74.9 nmol/l and
47
48 ≥ 75.0 nmol/l, which are widely used categories in studies of vitamin D levels. Values <50.0
49
50 nmol/l are usually regarded as representing vitamin D deficiency.[29]

51 **Covariate assessment**

52
53
54 Baseline age was categorized into 10-year intervals. Four categories of work status were
55
56 defined, the first comprising people being employed or carrying out professional work. The
57
58
59
60

1
2
3 second category included those temporarily out of work, students and individuals in military
4 service. The third category included pensioners and people receiving social security support,
5 and the fourth category represented women occupied full-time with housework. Those
6 currently working supplied information about physical activity at work,[30] in four categories
7 representing substantially sedentary work, work involving extensive walking, work leading to
8 both walking and lifting, and work involving particularly strenuous activities. For physical
9 activity in leisure time, including going to work, one category included those engaged in light
10 activity only or hard physical activity (leading to sweating or being out of breath) <1 hour per
11 week.[31] Other categories represented hard physical activity 1-2 and ≥ 3 hours per week.

12
13 Education was grouped according to duration as ≤ 9 , 10-12, or ≥ 13 years. Categories of
14 cigarette smoking represented current daily smoking, previous daily smoking and never daily
15 smoking. BMI, defined as $\text{weight}/\text{height}^2$ and computed in kg/m^2 , was subdivided into three
16 groups: <25, 25-29.9, ≥ 30 .

17
18 Season of blood sample collection was categorized as either the summer/autumn season (June
19 through November) or the winter/spring season (December through May). This subdivision
20 gives a marked difference in vitamin D deficiency between 6-months periods.[23]

21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 **Statistical methods**

36 Associations between 25(OH)D levels in serum and risk of chronic LBP were assessed by
37 unconditional logistic regression analysis with adjustment for potential confounders. Analyses
38 were performed separately with 25(OH)D levels as categorical and continuous variables. All
39 other variables were considered categorical. First, adjustments were carried out for age and
40 sex and a factor indicating which subsample each individual belonged to. Additional
41 adjustments for work status, physical activity at work and in leisure time, education, smoking,
42 BMI and season of blood sample collection were then introduced. Separate tests were
43 performed for interaction between continuous 25(OH)D level and all variables adjusted for.
44 Linearity in the association with continuous 25(OH)D level was tested for by adding a
45 quadratic term to the statistical model. All statistical analyses were carried out using IBM
46 SPSS version 23 (IBM Corp., Armonk, New York).

47
48 Separate analyses were limited to participants who had the blood samples drawn in the
49 summer/autumn season and the winter/spring season.

RESULTS

The age distribution was quite similar among cases and controls (table 1). The percentage of women was higher among cases than among controls. Within the three separate groups of serum 25(OH)D levels categorized as <50.0 nmol/l, 50.0-74.9 nmol/l and \geq 75.0 nmol/l, the percentage of persons with and without LBP at end of follow-up were almost the same among cases and controls (table 1).

Table 1 Number of individuals by age, sex, vitamin D status and case-control status

	Cases, with LBP at end of follow-up		Controls, without LBP at end of follow-up	
	Number	Percent	Number	Percent
Age groups (years)				
19-29	246	15	504	16
30-39	492	29	951	30
40-49	687	41	1191	38
50-55	260	15	491	16
Sex				
Female	1043	62	1677	54
Male	642	38	1460	47
25(OH)D (nmol/l)				
<50.0	925	55	1689	54
50.0-74.9	619	37	1126	36
\geq 75.0	141	8	322	10

LBP, low back pain.

Table 2 Descriptive statistics of 25(OH)D level by case-control status

	Cases, with LBP at end of follow-up				Controls, without LBP at end of follow-up			
	Number	Mean (nmol/l)	SD (nmol/l)	Median (nmol/l)	Number	Mean (nmol/l)	SD (nmol/l)	Median (nmol/l)
Total data set								
All seasons	1685	49.4	18.2	47.9	3137	50.0	19.1	48.0
Summer/autumn	773	54.1	18.4	52.0	1424	56.7	19.0	55.2
Winter/spring	912	45.4	17.0	43.8	1713	44.4	17.4	41.9
Women								
All seasons	1043	50.2	18.6	48.9	1677	50.5	19.0	49.0
Summer/autumn	480	53.8	18.7	52.9	784	56.2	18.7	54.4
Winter/spring	563	47.1	17.9	45.9	893	45.4	17.9	43.0
Men								
All seasons	642	48.0	17.4	45.8	1460	49.4	19.3	46.6
Summer/autumn	293	54.5	18.0	51.3	640	57.4	19.4	56.1
Winter/spring	349	42.6	14.9	40.8	820	43.2	16.7	40.4

LBP, low back pain; SD, standard deviation.

In the total data set, the mean serum 25(OH)D levels were quite similar among cases and controls (table 2). Both in women and men the serum 25(OH)D levels were higher in the summer/autumn than in the winter/spring season among cases and controls.

In the overall data set no association was found between vitamin D status and risk of LBP, neither with adjustment for age, sex and subsample nor with complete adjustment (OR per 10 nmol/l 25(OH)D= 1.01, 95% CI 0.97 to 1.06) (table 3). No significant interaction was found, but the interaction with sex was marginally significant (p=0.06). A weak positive association was suggested among women, although the estimated relation among men was in the opposite direction (table 3). Results did not differ significantly between subsamples.

Table 3 Associations between vitamin D status and risk of chronic LBP

	With adjustment for age, sex and subsample		With complete adjustment*	
	OR (95% CI)	p	OR (95% CI)	p
Total data set				
25(OH)D (nmol/l)		0.64 [†]		0.97 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	0.94 (0.80 to 1.11)		1.01 (0.85 to 1.20)	
≥75.0	0.90 (0.68 to 1.18)		0.98 (0.73 to 1.31)	
Per 10 nmol/l	0.99 (0.95 to 1.03)	0.59	1.01 (0.97 to 1.06)	0.59
Women				
25(OH)D (nmol/l)		0.54 [†]		0.27 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	1.09 (0.88 to 1.36)		1.20 (0.96 to 1.51)	
≥75.0	0.91 (0.64 to 1.30)		1.05 (0.72 to 1.52)	
Per 10 nmol/l	1.02 (0.97 to 1.08)	0.48	1.06 (1.00 to 1.12)	0.054
Men				
25(OH)D (nmol/l)		0.10 [†]		0.16 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	0.75 (0.57 to 0.98)		0.76 (0.57 to 1.01)	
≥75.0	0.90 (0.58 to 1.39)		0.88 (0.55 to 1.41)	
Per 10 nmol/l	0.94 (0.88 to 1.01)	0.10	0.94 (0.88 to 1.02)	0.13

*Adjustment for age, sex, work status, physical activity at work and in leisure time, education, smoking, BMI, subsample and season of blood sample collection.

[†]For categorical effect.

LBP, low back pain; OR, odds ratio; CI, confidence interval; BMI, body mass index.

Separate analyses of the association between vitamin D status and risk of LBP by season of blood sample collection revealed no effect in either sex in the summer/autumn season (table 4). However, in the winter/spring season associations differed significantly between women and men (p=0.004). In women a significant positive association was observed (OR per 10 nmol/l 25(OH)D =1.11, 95% CI 1.02 to 1.20) (table 4). In men the estimated association was

negative (OR per 10 nmol/l 25(OH)D =0.90, 95% CI 0.81 to 1.01) but did not reach statistical significance. Considering the different OR values from the categorical analyses, a consistent trend was suggested in each sex.

No significant deviations from linearity were observed in the relationships with 25(OH)D considered as a continuous variable.

Table 4 Associations between vitamin D status and risk of chronic LBP by season of blood sample collection*

	Summer/autumn		Winter/spring	
	OR (95% CI)	p	OR (95% CI)	p
Total data set				
25(OH)D (nmol/l)		0.87 [†]		0.79 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	0.93 (0.72 to 1.20)		1.08 (0.85 to 1.38)	
≥75.0	0.96 (0.66 to 1.39)		0.96 (0.58 to 1.58)	
Per 10 nmol/l	0.99 (0.93 to 1.06)	0.78	1.03 (0.97 to 1.10)	0.37
Women				
25(OH)D (nmol/l)		0.56 [†]		0.27 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	1.13 (0.81 to 1.57)		1.26 (0.92 to 1.73)	
≥75.0	0.89 (0.53 to 1.47)		1.34 (0.76 to 2.35)	
Per 10 nmol/l	1.00 (0.92 to 1.09)	0.94	1.11 (1.02 to 1.20)	0.012
Men				
25(OH)D (nmol/l)		0.15 [†]		0.20 [†]
<50.0	1.00 (Reference)		1.00 (Reference)	
50.0-74.9	0.70 (0.46 to 1.05)		0.84 (0.56 to 1.27)	
≥75.0	1.01 (0.58 to 1.76)		0.37 (0.12 to 1.17)	
Per 10 nmol/l	0.97 (0.88 to 1.08)	0.58	0.90 (0.81 to 1.01)	0.08

*Adjustment for age, sex, work status, physical activity at work and in leisure time, education, smoking, BMI and subsample.

[†]For categorical effect.

LBP, low back pain; OR, odds ratio; CI, confidence interval; BMI, body mass index.

DISCUSSION

The association between vitamin D status and chronic LBP was examined in a case-control study nested in a population-based follow-up of a Norwegian cohort. No association between vitamin D status and risk of LBP was found overall. For measurements in the winter/spring season, associations differed significantly between women and men. Among women a positive association was seen, but among men no significant association was observed.

A strength of the study is that the overwhelming majority of participants belonged to a homogeneous ethnic group.[32] Information was available on potential confounders, which made it possible to carry out accurate adjustments. The risk factor considered is represented by the vitamin D status measured in blood samples drawn at the clinical examination in HUNT2. However, the blood samples were stored for many years at low temperature, and the measurements of serum 25(OH)D levels were carried out in 2010 or in 2014/2015. Despite attempts to standardize the measurements, use of different instruments in the two periods may have led to minor systematic deviations in the 25(OH)D levels. To some extent, this was accounted for by adjusting all statistical analyses for subsample. This procedure was also essential in view of the different sampling procedures applied to establish the subsamples. The Liaison immunoassay method may still underestimate true 25(OH)D levels[33] and a direct comparison with values found by other methods may not be justified.[34]

A limitation is the lack of information about back pain occurring at other times in the 11-year follow-up interval between HUNT2 and HUNT3. The case definition only refers to the last year before collection of information in HUNT3. Thus all cases must have experienced incident chronic LBP during follow-up but so may some of the controls in the intervening period if they later recovered. Any real association between vitamin D status and LBP should be present anyhow but may be more difficult to detect. Furthermore, the extent of back pain was not characterized by the participants.

Another potential problem is the relatively long period between collection of information about risk factors and the recording of LBP status. In view of the weaker associations seen between 25(OH)D levels and mortality and cancer risk in prospective studies with longer follow-periods, it has been suggested that 25(OH)D levels should be measured at regular

1
2
3 intervals in prospective studies, perhaps every 2-4 years.[35] Such information was not
4 available in the present study. However, vitamin D levels have been shown to be relatively
5 stable over periods as long as 14 years in the Norwegian population,[36] and large data sets in
6 other countries have shown a definite degree of stability over somewhat shorter periods.[37,
7 38] In data with measurements from the HUNT2 survey, low 25(OH)D levels showed a clear
8 association with all-cause mortality in a prospective study with a median follow-up time of
9 18.5 years.[39] Thus potential relationships between 25(OH)D levels and disease should still
10 persist in a study such as the current one with 11 years of follow-up, although associations
11 may be attenuated. The state of relevant confounders may also change during a long follow-
12 up. An alternative to the design used here would be a cross-sectional case-control study based
13 on both 25(OH)D levels and reports of chronic LBP from the HUNT2 survey. Problems
14 concerning 25(OH)D levels changing over time would be eliminated but it would not be
15 possible to rule out an influence of disease on 25(OH)D status.
16
17
18
19
20
21
22
23
24

25 There are few population-based studies of relationships between vitamin D status and LBP.[9]
26 Some studies have investigated such relationships among patients,[11, 13, 16] but population-
27 based studies of risk of LBP with a prospective design have been lacking. The present study is
28 to our knowledge the only prospective study of the association between vitamin D status and
29 risk of LBP.
30
31
32
33

34 In cross-sectional population-based studies, an association between low level of 25(OH)D and
35 prevalence of back pain has been found in older women[9] and in schoolchildren.[18] Some
36 case-control studies have shown an association between low levels of vitamin D and
37 occurrence of back pain,[12, 14] but others do not support an association.[15, 17] In a recent
38 small Swedish case-control study no difference in vitamin D levels could be established
39 between participants with chronic LBP and matched controls.[17] This is consistent with the
40 overall results found in our study.
41
42
43
44
45

46 Among women with blood samples drawn in the winter/spring season, we found that high
47 levels of vitamin D were associated with an increased risk of LBP, which is the opposite of
48 what was initially hypothesized. In a Danish cross-sectional study of LBP patients an
49 association in the same direction was found, and normal levels of vitamin D, as opposed to
50 vitamin D deficiency, were associated with more Modic changes in the lumbar vertebral end
51 plates as seen on MRI.[16]
52
53
54
55
56
57
58
59
60

1
2
3 An association between vitamin D deficiency and adiposity has been found in several
4 studies.[21] This was also confirmed in a cross-sectional study in the HUNT population.[23]
5
6 In a prospective study using data from HUNT2 and HUNT3, overweight and obesity were
7
8 found to be associated with a predisposition to chronic LBP.[22] This suggests that BMI
9
10 could be a confounder in the association with 25(OH)D. However, our complete analyses
11
12 included adjustment for BMI, and it is not to be expected that any substantial relationship
13
14 should remain because of the association with adiposity.

15
16 In view of the seasonal variation in sun exposure, it is important to look at the time when
17
18 blood samples are collected to define vitamin D deficiency.[40] Thus in a study of bone
19
20 mineral density the summer season was found to be the best period to determine the serum
21
22 25(OH)D level.[41] This contrasts with our results, with a positive association between LBP
23
24 and vitamin D status observed in the winter/spring season for women only. Elevated levels of
25
26 25(OH)D may be harmful in other respects.[42] In a study of mortality among hospitalized
27
28 patients a U-shaped relationship was found, with both low and high values of 25(OH)D
29
30 associated with increased mortality.[42, 43] However, the 25(OH)D levels had to be
31
32 considerably above the typical values in the present study to be associated with higher
33
34 mortality and a causal relationship was not inferred, so such effects at the upper end of the
35
36 range for 25(OH)D are hardly relevant here. False U-shaped relationships between 25(OH)D
37
38 levels and health problems may easily appear when individuals with poor health have only
39
40 recently started using vitamin D supplement and are thus essentially misclassified.[44]

41
42 Gender and sex hormone levels are important variables that can influence a possible effect of
43
44 vitamin D in rheumatic diseases.[45] In a Danish population receiving UVB treatment, the
45
46 decline in 25(OH)D varied over time between sexes, with women maintaining a greater half-
47
48 life of 25(OH)D.[46] It is not evident, however, how such differences can explain the sex
49
50 contrast seen in the present study in the association with risk of LBP.

51
52 Measurements of 25(OH)D levels made during the winter/spring season may possibly capture
53
54 variability of vitamin D in a better way, because vitamin D values in winter are not so
55
56 dependent on sunlight exposure. It is possible, however, that women tending to report LBP in
57
58 this population are particularly health-conscious and use more vitamin D supplements during
59
60 the winter/spring season, creating a false positive association. Cod liver oil supplement has
traditionally represented a major source of vitamin D in Norway,[47] with about 35% of both
the male and female populations using such supplement in the 1990s.[48] Whole-year usage

1
2
3 among females is associated with poor perceived health but is otherwise associated with a
4 healthy diet,[47] suggesting that use of supplements is not in general matched to the vitamin
5 D needs.[47] In any case, the significant relationship observed among women may be
6 spurious due to the multiple statistical tests carried out. Thus this association cannot yet be
7 regarded as causal.
8
9

10
11 A basic biological relationship between vitamin D status and risk of LBP would be expected
12 to be similar in different populations. Unless the lack of overall association seen in the present
13 study represents a chance finding, the result should also apply to other populations. However,
14 the population distribution of vitamin D status may vary substantially between countries
15 because of differences in sunlight exposure and dietary conditions. Thus it is not obvious that
16 our main result can be generalized to other widely different populations, and further studies
17 are still called for.
18
19
20
21
22
23

24 25 26 27 **CONCLUSIONS**

28
29 In this population-based nested case-control study, no overall association between vitamin D
30 status and risk of LBP was found. The positive association observed in women with blood
31 samples drawn in the winter/spring season needs confirmation from other studies.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Acknowledgements** The Nord-Trøndelag Health Study (the HUNT study) is a collaboration
4 between the HUNT Research Centre, Faculty of Medicine and Health Science, the Norwegian
5 University of Science and Technology (NTNU); Norwegian Institute of Public Health;
6 Central Norway Health Authority; and the Nord-Trøndelag County Council. Laboratory
7 measurements were carried out at facilities owned by the Nord-Trøndelag Hospital Trust.
8
9
10

11
12
13
14 **Contributors** IngridH, IvarH, KH, XMM, AL and JAZ contributed to the study design.
15 IngridH and IvarH contributed to analysis and interpretation of data. IngridH wrote the paper.
16 IvarH, KH, XMM, AL and JAZ all revised the manuscript. All the authors have read and
17 approved the paper.
18
19
20
21

22
23
24 **Funding** Xiao-Mei Mai received funding from the Research Council of Norway for the
25 measurements of vitamin D in the first and second subsamples.
26
27
28

29
30 **Competing interests** None declared.
31
32

33
34
35 **Ethics approval** The work was approved by the Regional Committee for Medical and Health
36 Research Ethics in Central Norway, and HUNT was also approved by the Norwegian Data
37 Inspectorate. Each participant in the HUNT2 and HUNT3 surveys signed a written informed
38 consent regarding the collection and use of data for research purposes.
39
40
41

42
43
44 **Data sharing statement** The data set analysed belongs to a third party, the HUNT study (the
45 Nord-Trøndelag Health Study). The authors of the current manuscript are not affiliated with
46 the project as such, but have been given permission to analyse the data after obtaining the
47 necessary Norwegian permits. Because of the confidentiality requirements according to
48 Norwegian law, a data set of this kind with information from a complete county at the
49 individual level cannot be made public. However, research groups wishing to analyse data
50 from the HUNT study may apply to the HUNT organisation (<http://www.ntnu.edu/hunt>) to get
51 access to the data, after having obtained the permits needed according to Norwegian law.
52
53
54
55
56
57
58
59
60

References

- 1 Lambeek LC, Bosmans JE, Van Royen BJ, et al. Effect of integrated care for sick listed patients with chronic low back pain: Economic evaluation alongside a randomised controlled trial. *BMJ* 2010;341:c6414.
- 2 Maher C, Underwood M, Buchbinder R. Non-specific low back pain. *Lancet* 2017;389:736-47.
- 3 Holick MF. Vitamin D Deficiency. *N Engl J Med* 2007;357:266-81.
- 4 Wintermeyer E, Ihle C, Ehnert S, et al. Crucial role of vitamin D in the musculoskeletal system. *Nutrients* 2016;8:319.
- 5 Straube S, Moore RA, Derry S, et al. Vitamin D and chronic pain. *Pain* 2009;141:10-13.
- 6 Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. *Mayo Clin Proc* 2003;78:1463-70.
- 7 McBeth J, Pye SR, O'Neill TW, et al. Musculoskeletal pain is associated with very low levels of vitamin D in men: results from the European Male Ageing Study. *Ann Rheum Dis* 2010;69:1448-52.
- 8 Yong WC, Sanguaneko A, Upala S. Effect of vitamin D supplementation in chronic widespread pain: a systematic review and meta-analysis. *Clin Rheumatol* Published Online First: 15 Aug 2017. doi: 10.1007/s10067-017-3754-y
- 9 Hicks GE, Shardell M, Miller RR, et al. Associations between vitamin D status and pain in older adults: the Invecchiare in Chianti Study. *J Am Geriatr Soc* 2008;56:785-91.
- 10 Al Faraj S, Al Mutairi K. Vitamin D deficiency and chronic low back pain in Saudi Arabia. *Spine (Phila Pa 1976)* 2003;28:177-9.
- 11 Kim TH, Lee BH, Lee HM et al. Prevalence of vitamin D deficiency in patients with lumbar spinal stenosis and its relationship with pain. *Pain Physician* 2013;16:165-76.
- 12 Lotfi A, Abdel-Nasser AM, Hamdy A, et al. Hypovitaminosis D in female patients with chronic low back pain. *Clin Rheumatol* 2007;26:1895-901.

1
2
3 13 Ghai B, Bansal D, Kapil G, et al. High prevalence of hypovitaminosis D in Indian chronic
4 low back patients. *Pain Physician* 2015;18:E853-62.

5
6
7 14 Lodh M, Goswami B, Mahajan RD, et al. Assessment of vitamin D status in patients of
8 chronic low back pain of unknown etiology. *Indian J Clin Biochem* 2015;30:174-9.

9
10
11 15 Heidari B, Shirvani JS, Firouzbaji A, et al. Association between nonspecific skeletal pain
12 and vitamin D deficiency. *Int J Rheum Dis* 2010;13:340-6.

13
14
15 16 Johansen JV, Manniche C, Kjaer P. Vitamin D levels appear to be normal in Danish
16 patients attending secondary care for low back pain and a weak positive correlation between
17 serum level vitamin D and Modic changes was demonstrated: a cross-sectional cohort study
18 of consecutive patients with non-specific low back pain. *BMC Musculoskelet Disord*
19 2013;14:78.

20
21
22 23 17 Thörneby A, Nordeman LM, Johanson EH. No association between level of vitamin D and
24 chronic low back pain in Swedish primary care: a cross-sectional case-control study. *Scand J*
25 *Prim Health Care* 2016;34:196-204.

26
27
28 29 18 Alghadir AH, Gabr SA, Al-Eisa ES. Mechanical factors and vitamin D deficiency in
30 schoolchildren with low back pain: biochemical and cross-sectional survey analysis. *J Pain*
31 *Res* 2017;10:855-65.

32
33
34 35 19 Sandoughi M, Zakeri Z, Mirhosainee Z, et al. The effect of vitamin D on nonspecific low
36 back pain. *Int J Rheum Dis* 2015;18:854-8.

37
38
39 40 20 Mai XM, Chen Y, Camargo CA Jr, et al. Cross-sectional and prospective cohort study of
41 serum 25-hydroxyvitamin D level and obesity in adults: the HUNT Study. *Am J Epidemiol*
42 2012;175:1029-36.

43
44
45 46 21 Earthman CP, Beckman LM, Masodkar K, et al. The link between obesity and low
47 circulating 25-hydroxyvitamin D concentrations: considerations and implications. *Int J Obes*
48 *(Lond)* 2012;36:387-96.

49
50
51 52 22 Heuch I, Heuch I, Hagen K, et al. Body mass index as a risk factor for developing chronic
53 low back pain: a follow-up in the Nord-Trøndelag Health Study. *Spine (Phila Pa 1976)*
54 2013;38:133-9.

- 1
2
3 23 Larose TL, Chen Y, Camargo CA Jr, et al. Factors associated with vitamin D deficiency in
4 a Norwegian population: the HUNT Study. *J Epidemiol Community Health* 2014;68:165-70.
5
6
7 24 Holick MF. Resurrection of vitamin D deficiency and rickets. *J Clin Invest*
8
9 2006;116:2062-72.
10
11 25 Krokstad S, Langhammer A, Hveem K, et al. Cohort profile: the HUNT Study, Norway.
12
13 *Int J Epidemiol* 2013;42:968-77.
14
15 26 Mai XM, Langhammer A, Camargo CA Jr, et al. Serum 25-hydroxyvitamin D levels and
16
17 incident asthma in adults: the HUNT Study. *Am J Epidemiol* 2012;176:1169-76.
18
19 27 Larose TL, Langhammer A, Chen Y, et al. Serum 25-hydroxyvitamin D levels and lung
20
21 function in adults with asthma: the HUNT Study. *Eur Respir J* 2015;45:1019-26.
22
23 28 Passing H, Bablok W. A new biometrical procedure for testing the equality of
24
25 measurements from two different analytical methods. Application of linear regression
26
27 procedures for method comparison studies in clinical chemistry, Part I. *J Clin Chem Clin*
28
29 *Biochem* 1983;21:709-20.
30
31 29 Ross AC, Manson JE, Abrams SA, et al. The 2011 dietary reference intakes for calcium
32
33 and vitamin D: what dietetics practitioners need to know. *J Am Diet Assoc* 2011;111:524-7.
34
35 30 Heuch I, Heuch I, Hagen K, et al. Physical activity level at work and risk of chronic low
36
37 back pain: A follow-up in the Nord-Trøndelag Health Study. *PLoS One* 2017;12:e0175086.
38
39 31 Heuch I, Heuch I, Hagen K, et al. Is there a U-shaped relationship between physical
40
41 activity in leisure time and risk of chronic low back pain? A follow-up in the HUNT Study.
42
43 *BMC Public Health* 2016;16:306.
44
45 32 Holmen J, Midthjell K, Krüger Ø, et al. The Nord-Trøndelag Health Study 1995–97
46
47 (HUNT 2): objectives, contents, methods and participation. *Nor Epidemiol* 2003;13:19-32.
48
49 33 Schöttker B, Jansen EH, Haug U, et al. Standardization of misleading immunoassay based
50
51 25-hydroxyvitamin D levels with liquid chromatography tandem-mass spectrometry in a large
52
53 cohort study. *PLoS One* 2012;7:e48774.
54
55
56
57
58
59
60

- 1
2
3 34 Carter GD, Berry J, Durazo-Arvizu R, et al. Hydroxyvitamin D assays: An historical
4 perspective from DEQAS. *J Steroid Biochem Mol Biol* Published Online First: 20 Jul 2017.
5 doi: 10.1016/j.jsbmb.2017.07.018
6
7
8
9 35 Grant WB. Effect of follow-up time on the relation between prediagnostic serum 25-
10 hydroxyvitamin D and all-cause mortality rate. *Dermatoendocrinol* 2012;4:198-202.
11
12
13 36 Jorde R, Sneve M, Hutchinson M, et al. Tracking of serum 25-hydroxyvitamin D levels
14 during 14 years in a population-based study and during 12 months in an intervention study.
15 *Am J Epidemiol* 2010;171:903-8.
16
17
18 37 Saliba W, Barnett O, Stein N, et al. The longitudinal variability of serum 25(OH)D levels.
19 *Eur J Intern Med* 2012;23:e106-11.
20
21
22
23 38 Schöttker B, Haug U, Schomburg L, et al. Strong associations of 25-hydroxyvitamin D
24 concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a
25 large cohort study. *Am J Clin Nutr* 2013;97:782-93.
26
27
28
29 39 Sun YQ, Langhammer A, Skorpen F, et al. Serum 25-hydroxyvitamin D level, chronic
30 diseases and all-cause mortality in a population-based prospective cohort: the HUNT Study,
31 Norway. *BMJ Open* 2017;7:e017256.
32
33
34 40 Schramm S, Lahner H, Jöckel KH, et al. Impact of season and different vitamin D
35 thresholds on prevalence of vitamin D deficiency in epidemiological cohorts—a note of
36 caution. *Endocrine* 2017;56:658-66.
37
38
39
40 41 Michaëlsson K, Wolk A, Byberg L, et al. The seasonal importance of serum 25-
41 hydroxyvitamin D for bone mineral density in older women. *J Intern Med* 2017;281:167-78.
42
43
44 42 Drake MT. Vitamin D and the goldilocks principle: too little, too much, or just right? *J*
45 *Clin Endocrinol Metab* 2014;99:1164-6.
46
47
48
49 43 Amrein K, Quraishi SA, Litonjua AA, et al. Evidence for a U-shaped relationship between
50 prehospital vitamin D status and mortality: a cohort study. *J Clin Endocrinol Metab*
51 2014;99:1461-9.
52
53
54 44 Grant WB, Karras SN, Bischoff-Ferrari HA, et al. Do studies reporting 'U'-shaped serum
55 25-hydroxyvitamin D-health outcome relationships reflect adverse effects?
56 *Dermatoendocrinol* 2016;8:e1187349.
57
58
59
60

1
2
3 45 Vasile M, Corinaldesi C, Antinozzi C, et al. Vitamin D in autoimmune rheumatic diseases:
4 A view inside gender differences. *Pharmacol Res* 2017;117:228-41.
5
6

7 46 Datta P, Philipsen PA, Olsen P, et al. The half-life of 25(OH)D after UVB exposure
8 depends on gender and vitamin D receptor polymorphism but mainly on the start level.
9 *Photochem Photobiol Sci* 2017;16:985-95.
10
11

12 47 Brustad M, Braaten T, Lund E. Predictors for cod-liver oil supplement use – the
13 Norwegian Women and Cancer Study. *Eur J Clin Nutr* 2004;58:128-36.
14
15

16 48 Alexander J, Frøyland L, Hemre GI, et al. A comprehensive assessment of fish and other
17 seafood in the Norwegian diet. Oslo: Norwegian Scientific Committee for Food Safety 2006.
18
19
20
21
22
23
24

25 **Figure legend**

26
27
28 **Figure 1** Flow chart showing participants for statistical analysis in the nested case-control
29 study.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 Flow chart showing participants for statistical analysis in the nested case-control study.

254x338mm (300 x 300 DPI)

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any pre-specified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	5-6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5-7
Bias	9	Describe any efforts to address potential sources of bias	12-13
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7
		(b) Describe any methods used to examine subgroups and interactions	7
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	5-6

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	5-6
		(b) Give reasons for non-participation at each stage	5-6
		(c) Consider use of a flow diagram	5-6
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8-9
		(b) Indicate number of participants with missing data for each variable of interest	6
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	NA
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	8
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	6-7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9-11
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	12-13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.